var title_f23_2_23584="Developmental milestones 24 through 42 mos B";
var content_f23_2_23584=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 630px\">",
"   <div class=\"ttl\">",
"    Developmental milestones: 24 months through 3 years 6 months (continued)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 610px; height: 297px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     &copy; 2007 Chris Johnson, MD, AAP Council on Children with Disabilities. Adapted with permission and contributions from: Frances Page Glascoe, PhD and Nicholas Robertshaw, authors of PEDS:Developmental Milestones; Franklin Trimm, MD, Vice Chair of Pediatrics, USA/APA Education Committee; the Center for Disease Control \"Act Early\" Initiative; the National Institute for Literacy/Reach Out and Read; and the Inventory of Early Development by Albert Brigance published by Curriculum Associates, Inc. Permission is granted to reproduce these pages on the condition that they are only used as guide to average development and not as a substitute for standardized validated screening for developmental-behavioral problems.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_2_23584=[""].join("\n");
var outline_f23_2_23584=null;
var title_f23_2_23585="External rotation test";
var content_f23_2_23585=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57983&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57983&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    External rotation test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 479px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The infraspinatus muscle is primarily responsible for external rotation of the shoulder. The muscle can be tested by having the patient attempt to externally rotate against resistance, as shown in the photograph above. The shoulder is held in adduction and the elbow bent to 90 degrees during testing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_2_23585=[""].join("\n");
var outline_f23_2_23585=null;
var title_f23_2_23586="Normal AP and lateral elbow radiograph child";
var content_f23_2_23586=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56647&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56647&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    AP and lateral radiographs of the normal elbow and anatomic landmarks",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Anteroposterior radiograph of a normal elbow of a child. (B) Normal lateral radiograph. The radial head and neck are seen on both AP and lateral views of the elbow. The olecranon process of the ulna is best seen on the lateral view. On the lateral radiograph, the radial head is superimposed over the coronoid process of the ulna.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bachman D, Santora S. Orthopedic trauma. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FR (Eds), Lippincott Williams &amp; Wilkins 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_2_23586=[""].join("\n");
var outline_f23_2_23586=null;
var title_f23_2_23587="Prostate adenocarcinoma3 light";
var content_f23_2_23587=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F77354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F77354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prostate cancer and prominent nucleoli",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 373px; height: 274px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power photomicrograph of an hematoxylin and eosin stained prostate gland demonstrating prostate adenocarcinoma. The prominent nucleoli and amphophilic cytoplasm of adenocarcinoma (arrows) can be compared to the large adjacent benign gland taking up the entire right half of the tissue section.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ximing Yang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_2_23587=[""].join("\n");
var outline_f23_2_23587=null;
var title_f23_2_23588="Etiology renal agenesis";
var content_f23_2_23588=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diagram of normal and abnormal kidney development",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 404px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Uppermost are the precursor structures of a single renal tract, as would be present in a human fetus of 4-5 weeks' gestation; note the mesonephric duct, metanephric mesenchyme (which will form nephrons), and ureteric bud. Solid arrows indicate normal developmental pathways and dotted arrows indicate abnormal pathways. In normal development, the ureteric bud grows into the metanephric mesenchyme and is followed by bud branching and nephron induction and, finally, development of a fully functional, normal kidney containing multiple layers of nephrons. Hypoplastic kidneys contain fewer layers of nephrons than normal but retain a moderated degree of excretory function. Cystic dysplastic kidneys contain malformed tubules and some small cysts but generally retain some excretory function. A discrete renal pelvis (white) is present in normal, hypoplastic and cystic dysplastic kidneys; this feature would appear distended (hydronephrotic) if the kidney was attached to an obstructed lower tract (not shown). The multicystic dysplastic kidney has no useful excretory function and its pelvis is absent or severely disorganized. Aplastic kidneys undergo no primary growth or development; a similar phenotype is seen in the organ remnant left after the spontaneous involution of a multicystic dysplastic kidney. In the most profound type of malformation, agenesis, the first steps of kidney development do not occur and the kidney (and often the ureter) is absent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted by permission from MacMillan Publishers Ltd. Kerecuk, L, Schreuder, MF, Woolf, AS. Renal tract malformations: perspectives for nephrologists. Nat Clin Pract Nephrol 2008; 4:312. Copyright &copy;2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_2_23588=[""].join("\n");
var outline_f23_2_23588=null;
var title_f23_2_23589="Trimethoprim-sulfamethoxazole (co-trimoxazole): Patient drug information";
var content_f23_2_23589=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Trimethoprim-sulfamethoxazole (co-trimoxazole): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     see \"Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"     see \"Trimethoprim-sulfamethoxazole (co-trimoxazole): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F154885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bactrim&trade;;",
"     </li>",
"     <li>",
"      Bactrim&trade; DS;",
"     </li>",
"     <li>",
"      Septra&reg; DS",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F154886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Sulfatrim&reg;;",
"     </li>",
"     <li>",
"      Apo-Sulfatrim&reg; DS;",
"     </li>",
"     <li>",
"      Apo-Sulfatrim&reg; Pediatric;",
"     </li>",
"     <li>",
"      Novo-Trimel;",
"     </li>",
"     <li>",
"      Novo-Trimel D.S.;",
"     </li>",
"     <li>",
"      Nu-Cotrimox;",
"     </li>",
"     <li>",
"      Septra&reg; Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691909",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700982",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not give this drug to an infant younger than 2 months of age.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702970",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sulfamethoxazole, trimethoprim, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703223",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Anemia caused by a lack of folic acid, very bad kidney disease, or very bad liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant and near term.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store as you have been told by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11061 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-87E6A227E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_2_23589=[""].join("\n");
var outline_f23_2_23589=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154885\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154886\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022025\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022027\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022026\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022031\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022032\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022034\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022029\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022030\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022035\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022036\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=related_link\">",
"      Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=related_link\">",
"      Trimethoprim-sulfamethoxazole (co-trimoxazole): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_2_23590="Fibrous trabeculae in thymoma";
var content_f23_2_23590=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thymoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 230px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photomicrograph shows the multilobulated architecture characteristic of thymoma, with thick fibrous trabeculae that separate the tumor into lobules of varying size. (Hematoxylin and eosin, magnification 25x).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Travis, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_2_23590=[""].join("\n");
var outline_f23_2_23590=null;
var title_f23_2_23591="Basic case 8";
var content_f23_2_23591=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1108px;\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Basic case 8",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 113px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_2_23591=[""].join("\n");
var outline_f23_2_23591=null;
var title_f23_2_23592="Algorithm for risk assessment TLS";
var content_f23_2_23592=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F63724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F63724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 526px\">",
"   <div class=\"ttl\">",
"    Algorithmic approach to risk assessment of tumor lysis syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 506px; height: 582px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ULN = Upper limit of normal",
"    </div>",
"    <div class=\"reference\">",
"     Modified from Howard SC, Jones DP, Pui CH. The Tumor Lysis Syndrome. N Engl J Med 2011; 364:1844.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_2_23592=[""].join("\n");
var outline_f23_2_23592=null;
var title_f23_2_23593="Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness";
var content_f23_2_23593=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/2/23593/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/2/23593/contributors\">",
"     Sara F Forman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/2/23593/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/2/23593/contributors\">",
"     Joel Yager, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/2/23593/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/2/23593/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/2/23593/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many aspects of the United States culture display an obsession with weight loss. Women's magazines typically have a cover highlighting a story about weight management, dieting hints, or how to tighten specific muscle groups. Models and actors display an unattainable level of thinness. Some athletes relentlessly pursue a leaner body for performance enhancement.",
"   </p>",
"   <p>",
"    Our culture's obsession to achieve lower weight conveys an unavoidable message to maturing adolescents. According to the 2007 Youth Risk Behavior Survey, 35 percent of adolescent girls believed that they were overweight and 60 percent were attempting to lose weight. In the 30 days before questioning, 8 percent of adolescent girls reported that they had tried vomiting or had taken laxatives to help control their weight.",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, and clinical features of eating disorders are reviewed here. Treatment and outcomes of eating disorders; medical complications of eating disorders and their management; evaluation for medical complications and criteria for hospitalization; and the refeeding syndrome in anorexia nervosa are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44023?source=see_link\">",
"       \"Eating disorders: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38890?source=see_link\">",
"       \"Anorexia nervosa in adults and adolescents: Medical complications and their management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33816?source=see_link\">",
"       \"Bulimia nervosa and binge eating disorder in adults: Medical complications and their management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16550?source=see_link\">",
"       \"Anorexia nervosa in adults: Evaluation for medical complications and criteria for hospitalization to manage these complications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/16/30982?source=see_link\">",
"       \"Anorexia nervosa in adults and adolescents: The refeeding syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the American Psychiatric Association's Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR), eating disorders include [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anorexia nervosa",
"     </li>",
"     <li>",
"      Bulimia nervosa",
"     </li>",
"     <li>",
"      Eating disorders not otherwise specified",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Anorexia nervosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;The DSM-IV-TR criteria for anorexia nervosa include refusal to maintain body weight at or above a minimally normal weight for age and height, intense fear of gaining weight or becoming fat despite being underweight, distorted perception of body weight and shape, and amenorrhea (",
"    <a class=\"graphic graphic_table graphicRef75110 \" href=\"UTD.htm?9/7/9339\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/1\">",
"     1",
"    </a>",
"    ]. The diagnosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/7/3194?source=see_link&amp;anchor=H173811834#H173811834\">",
"     \"Anorexia nervosa in adults: Diagnosis, associated clinical features, and assessment\", section on 'Diagnostic criteria'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/7/3194?source=see_link&amp;anchor=H29336352#H29336352\">",
"     \"Anorexia nervosa in adults: Diagnosis, associated clinical features, and assessment\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Bulimia nervosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;The DSM-IV-TR criteria for bulimia nervosa include recurrent episodes of binge eating and inappropriate compensatory behavior to prevent weight gain, occurring on average at least two times per week for three months (",
"    <a class=\"graphic graphic_table graphicRef70006 \" href=\"UTD.htm?2/46/2796\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/1\">",
"     1",
"    </a>",
"    ]. The diagnosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33577?source=see_link&amp;anchor=H22668229#H22668229\">",
"     \"Bulimia nervosa in adults: Clinical features, diagnosis, and assessment\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33577?source=see_link&amp;anchor=H22668250#H22668250\">",
"     \"Bulimia nervosa in adults: Clinical features, diagnosis, and assessment\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Eating disorder not otherwise specified",
"    </span>",
"    &nbsp;&mdash;&nbsp;DSM-IV-TR also includes a definition for Eating Disorder Not Otherwise Specified (ED-NOS) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/1\">",
"     1",
"    </a>",
"    ]. This category includes patients with clearly aberrant eating patterns and weight management habits who do not meet the criteria for anorexia nervosa or bulimia nervosa. The most notable prototypes are binge eating disorder, night eating syndrome, sleep related eating disorder, and purging disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Binge-eating disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to research criteria, binge-eating disorder is defined as eating an amount of food in a discrete period of time that is definitely larger than most people would eat in a similar period of time under similar circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/1\">",
"     1",
"    </a>",
"    ]. These episodes occur at least twice a week for at least six months. Episodes of binge eating are associated with a lack of control and with distress over the eating. Additional information about the definition of binge-eating disorder, as well as the epidemiology, treatment planning, and use of cognitive-behavior therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34841?source=see_link\">",
"     \"Binge-eating disorder: Overview of treatment in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/28/8646?source=see_link\">",
"     \"Binge-eating disorder: Cognitive-behavioral therapy (CBT)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trends in the epidemiology of eating disorders are difficult to assess because of changes in the diagnostic criteria over time, and because detection by self-report may not be reliable in an illness characterized by secrecy and denial [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/2\">",
"     2",
"    </a>",
"    ]. Most studies report increased prevalence over the past 50 years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/3\">",
"     3",
"    </a>",
"    ], although trends over the past 10 years are debated. One study among college students in California noted a decrease in",
"    <span class=\"nowrap\">",
"     binge/purge",
"    </span>",
"    behaviors from the 1980s to the 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/4\">",
"     4",
"    </a>",
"    ]. However, most clinicians believe that increased numbers of eating disordered patients are presenting to their practices.",
"   </p>",
"   <p>",
"    The lifetime prevalence of anorexia nervosa in women is estimated to be 0.3 to 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/5\">",
"     5",
"    </a>",
"    ]. Rates for men are significantly lower. Data from the National Comorbidity Replication survey indicate a lifetime prevalence of 0.9 and 0.3 percent for women and men respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/6\">",
"     6",
"    </a>",
"    ]. Data from a Finnish birth cohort study suggest a higher lifetime prevalence (2.2 percent), with inclusion of untreated cases identified by screening [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bulimia nervosa is now diagnosed using more stringent criteria in the DSM-IV than in earlier editions of the DSM. This, combined with the shorter length of time that this illness has been recognized, clouds interpretation of epidemiologic data. Prevalence rates of 1 to 1.5 percent of women have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. Rates for younger adolescents are generally lower than those for college students.",
"   </p>",
"   <p>",
"    ED-NOS occurs in approximately 3 to 5 percent of women between the ages of 15 and 30 in Western countries [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/9\">",
"     9",
"    </a>",
"    ]. Eating disorders have become more common among minority culture groups as these groups become assimilated into American society [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The estimated lifetime prevalence of bulimia nervosa is 1 to 3 percent and for anorexia nervosa is 0.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/1\">",
"     1",
"    </a>",
"    ]. Many more have disordered eating and meet criteria for ED-NOS. There are two peaks of the onset for anorexia nervosa, at ages 14 and 18, though patients may present from late childhood through adulthood.",
"   </p>",
"   <p>",
"    The epidemiology of binge-eating disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34841?source=see_link&amp;anchor=H103238672#H103238672\">",
"     \"Binge-eating disorder: Overview of treatment in adults\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Males with eating disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;More males sought treatment for eating disorders in the 1990s than in the 1980s [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/11\">",
"     11",
"    </a>",
"    ]. It is unclear whether this reflects an increase in prevalence or that males are seeking treatment more often. Two studies have found that male and female anorexia nervosa patients have similar family histories of eating disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus regarding the causes of eating disorders. A combination of genetic, biological, psychological, family, environmental, and social factors probably contribute to developing an eating disorder. An anxious or perfectionistic individual may experience decreased self-esteem or self-control because of predisposing factors (eg, biology, family history, traumatic events) and then use dieting behavior or weight loss to provide a sense of stability or control [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of factors have been noted to be associated with the development of eating disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, a history of dieting was the most important predictor of a new eating disorder in adolescent children [",
"      <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Childhood preoccupation with a thin body and social pressure about weight are associated with the development of binge eating disorders in adolescence [",
"      <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sports and artistic endeavors in which leanness is emphasized (eg, ballet, running, or wrestling) and sports in which scoring is partly subjective (eg, skating or gymnastics) are associated with a higher incidence of eating disorders. Young women with restrictive eating disorders and amenorrhea have been referred to as having the \"female athlete triad,\" which consists of an eating disorder, amenorrhea, and osteoporosis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36919?source=see_link\">",
"       \"Amenorrhea and infertility associated with exercise\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Studies conflict about the association of eating disorders and sexual abuse. One study reported an association between childhood sexual abuse and bulimia nervosa, but not anorexia nervosa [",
"      <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A role for genetics in the pathogenesis of eating disorders is supported by studies that found that young women whose first degree relatives have eating disorders were at a six- to ten-fold increased risk for developing an eating disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/19\">",
"     19",
"    </a>",
"    ]. Monozygotic twins have a higher rate of concordance for eating disorders compared with dizygotic twins [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. There is also a higher prevalence of affective disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/22\">",
"     22",
"    </a>",
"    ] and alcoholism [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/23\">",
"     23",
"    </a>",
"    ] in first-degree relatives of patients with eating disorders. Linkage analysis studies have found a susceptibility locus for bulimia nervosa on chromosome 10p [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/24\">",
"     24",
"    </a>",
"    ] and for anorexia nervosa on chromosome 1p [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Psychiatric problems are common in patients with eating disorders, including affective disorders, anxiety disorders, obsessive-compulsive disorder, and personality disorders, tobacco and other substance abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/22,26\">",
"     22,26",
"    </a>",
"    ]. Adult women with eating disorders appear to have had higher rates of obsessive-compulsive personality traits in childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/27\">",
"     27",
"    </a>",
"    ]. Alcohol problems are more prevalent among those with bulimia nervosa than among patients with restrictive anorexia nervosa [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Family distress of any kind can be a significant factor in the development of an eating disorder. No strong empirical data support a particular family prototype that enhances the development of eating disorders. Family characteristics associated with eating disorders may include high perceived parental expectations for achievement and appearance, families who have difficulties managing conflict, poor communication style (particularly related to feelings), enmeshment and, less frequently, estrangement between family members, devaluation of the mother or the maternal role, and marital tension. Families struggling with an eating disorder often have difficulties responding positively to the changing physical and emotional needs of their adolescent. As with other psychiatric disorders, in families that are highly critical of the patient (so-called &ldquo;high expressed emotion&rdquo; families) outcomes are less favorable [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Role of the central nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurotransmitters may have a role in the pathogenesis of anorexia nervosa. Decreased levels of the neurotransmitter norepinephrine may partially account for the bradycardia and hypotension seen with starvation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/29\">",
"     29",
"    </a>",
"    ]. Serotonin plays a role in the brain's appetite and satiety centers and may account for some neuropsychiatric changes and loss of appetite [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/30\">",
"     30",
"    </a>",
"    ]. One study, for example, found that serotonin metabolite levels were high in anorectic patients after weight restoration [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/31\">",
"     31",
"    </a>",
"    ]. Stimulation of serotonin (5-HT4) receptors in the brain reward center of mice reduced their eating drive; these receptors also mediate the anorectic effect of the \"club drug\" ecstasy in mice, suggesting a possible path for the addictive aspect of anorexia nervosa [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MRI studies have shown brain changes in patients with anorexia nervosa, including decreased volumes in the gray and white matter with increased CSF volume [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/33\">",
"     33",
"    </a>",
"    ]. Another report found that the grey matter volumes did not entirely normalize and cerebrospinal fluid volume remained significantly increased compared with controls after weight recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/34\">",
"     34",
"    </a>",
"    ]. In comparison, white matter did not significantly differ from controls after weight recovery. The significance of these findings is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PRESENTATION AND SCREENING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Anorexia nervosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;The core features of anorexia nervosa are an abnormally low body weight, intense fear of gaining weight, distorted perception of body weight and shape, and amenorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/1\">",
"     1",
"    </a>",
"    ]. The clinical features of anorexia nervosa are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/7/3194?source=see_link&amp;anchor=H29336301#H29336301\">",
"     \"Anorexia nervosa in adults: Diagnosis, associated clinical features, and assessment\", section on 'Associated clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/7/3194?source=see_link&amp;anchor=H173811834#H173811834\">",
"     \"Anorexia nervosa in adults: Diagnosis, associated clinical features, and assessment\", section on 'Diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Bulimia nervosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;The core features of bulimia nervosa are binge eating (ie, eating an amount of food that is definitely larger than most people would eat under similar circumstances) and inappropriate compensatory behavior to prevent weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/1\">",
"     1",
"    </a>",
"    ]. The prototypic sequence of behavior in bulimia nervosa consists of caloric restriction, binge eating, and self-induced vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/35\">",
"     35",
"    </a>",
"    ]. The clinical features of bulimia nervosa are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33577?source=see_link&amp;anchor=H8041571#H8041571\">",
"     \"Bulimia nervosa in adults: Clinical features, diagnosis, and assessment\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33577?source=see_link&amp;anchor=H15893577#H15893577\">",
"     \"Bulimia nervosa in adults: Clinical features, diagnosis, and assessment\", section on 'Comorbid psychopathology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Screening tools",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other instruments have been developed to identify patients with eating disorders. Some are long and not ideally suited for screening in a primary care setting. At least two shorter instruments have been developed and, although neither has been extensively validated, may help identify patients who need further evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest the SCOFF questionnaire, which consists of five questions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/36,38\">",
"     36,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Do you make yourself",
"      <strong>",
"       S",
"      </strong>",
"      ick because you feel uncomfortably full?",
"     </li>",
"     <li>",
"      Do you worry you have lost",
"      <strong>",
"       C",
"      </strong>",
"      ontrol over how much you eat?",
"     </li>",
"     <li>",
"      Have you recently lost more than",
"      <strong>",
"       O",
"      </strong>",
"      ne stone (14 pounds or 6.35 kg) in a three month period?",
"     </li>",
"     <li>",
"      Do you believe yourself to be",
"      <strong>",
"       F",
"      </strong>",
"      at when others say you are too thin?",
"     </li>",
"     <li>",
"      Would you say that",
"      <strong>",
"       F",
"      </strong>",
"      ood dominates your life?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A second short tool, the Eating disorder Screen for Primary care (ESP), has also been evaluated as a screening tool for eating disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Are you satisfied with your eating patterns? (No is abnormal)",
"     </li>",
"     <li>",
"      Do you ever eat in secret? (Yes is abnormal)",
"     </li>",
"     <li>",
"      Does your weight affect the way you feel about yourself? (Yes is abnormal)",
"     </li>",
"     <li>",
"      Have any members of your family suffered with an eating disorder? (Yes is abnormal)",
"     </li>",
"     <li>",
"      Do you currently suffer with or have you ever suffered in the past with an eating disorder? (Yes is abnormal)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The original study describing the SCOFF reported that a \"yes\" to two or more questions was associated with a sensitivity and specificity of 100 and 87.5 percent for the diagnosis of an eating disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/36\">",
"     36",
"    </a>",
"    ]. A subsequent report that proposed and evaluated the ESP found that two abnormal responses to the ESP had a sensitivity and specificity of 100 and 71 percent, and that the sensitivity and specificity of SCOFF was lower (78 and 88 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/37\">",
"     37",
"    </a>",
"    ]. Further validation of both of these instruments is needed in broader populations.",
"   </p>",
"   <p>",
"    The Eating Attitudes Test (EAT) is one of the most widely used self-report eating disorder instruments. The 26-item version has an accuracy rate of at least 90 percent when screening patients for the presence of a DSM-IV eating disorder, using a cutoff score of 20 (",
"    <a class=\"graphic graphic_table graphicRef60963 \" href=\"UTD.htm?7/56/8079\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Primary Care Evaluation of Mental Disorders Patient Health Questionnaire is a brief instrument that both screens for and provides a categorical DSM-IV diagnosis for bulimia nervosa, as well as depressive, anxiety, alcohol, and somatoform disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/40\">",
"     40",
"    </a>",
"    ]. It was specifically designed for use in primary care, is fully self-administered by the patient, has good diagnostic validity overall (sensitivity 75 percent, specificity 90 percent), excellent diagnostic validity for eating disorders (sensitivity 89 percent, specificity 96 percent), and the median physician time to review the results is one to two minutes (",
"    <a class=\"graphic graphic_table graphicRef82674 \" href=\"UTD.htm?21/32/22019\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Additional information about assessment of patients with bulimia nervosa is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33577?source=see_link&amp;anchor=H22668257#H22668257\">",
"     \"Bulimia nervosa in adults: Clinical features, diagnosis, and assessment\", section on 'Assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MEDICAL EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H260809155\">",
"    <span class=\"h2\">",
"     Anorexia nervosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with anorexia nervosa should be evaluated for medical complications (",
"    <a class=\"graphic graphic_table graphicRef67080 \" href=\"UTD.htm?29/44/30413\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/10,41\">",
"     10,41",
"    </a>",
"    ]. The complications and their signs and symptoms are secondary to caloric restriction and weight loss. The evaluation should include a history, physical examination, and laboratory testing. The evaluation for medical complications and criteria for hospitalization to manage these complications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16550?source=see_link\">",
"     \"Anorexia nervosa in adults: Evaluation for medical complications and criteria for hospitalization to manage these complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H260809232\">",
"    <span class=\"h2\">",
"     Bulimia nervosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with bulimia nervosa should be evaluated for medical complications [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/10,41\">",
"     10,41",
"    </a>",
"    ]. The complications and their signs and symptoms are secondary to persistent purging. The evaluation should include a history, physical examination, and laboratory testing. The evaluation for medical complications and criteria for hospitalization to manage these complications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33816?source=see_link\">",
"     \"Bulimia nervosa and binge eating disorder in adults: Medical complications and their management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44023?source=see_link&amp;anchor=H17#H17\">",
"     \"Eating disorders: Treatment\", section on 'Criteria for hospitalization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MEDICAL COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many medical complications can occur during starvation or persistent purging [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/10,41-43\">",
"     10,41-43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95585531\">",
"    <span class=\"h2\">",
"     Anorexia nervosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of anorexia nervosa include myocardial atrophy, mitral valve prolapse, pericardial effusion, bradycardia, functional hypothalamic amenorrhea, antenatal and postpartum problems, osteoporosis, gastroparesis, and constipation (",
"    <a class=\"graphic graphic_table graphicRef67080 \" href=\"UTD.htm?29/44/30413\">",
"     table 5",
"    </a>",
"    ). In addition, growth disturbance can occur in adolescents. Medical complications of anorexia nervosa and their management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38890?source=see_link\">",
"     \"Anorexia nervosa in adults and adolescents: Medical complications and their management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95585538\">",
"    <span class=\"h2\">",
"     Bulimia nervosa and binge eating disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of bulimia nervosa include dehydration, hypokalemia, menstrual irregularities, Mallory-Weiss syndrome, ipecac-induced myopathy, and erosion of dental enamel. Electrocardiogram changes can occur in both disorders. Medical complications of bulimia nervosa and binge eating disorder, and their management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33816?source=see_link\">",
"     \"Bulimia nervosa and binge eating disorder in adults: Medical complications and their management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18369703\">",
"    <span class=\"h1\">",
"     COURSE OF ILLNESS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H851980\">",
"    <span class=\"h2\">",
"     Anorexia nervosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcome studies have focused upon anorexia nervosa [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. One review found that approximately 50 percent of patients have good outcomes (defined by return of menses and weight gain), 25 percent have intermediate outcomes, and 25 percent have a poor outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of patients with anorexia nervosa have a bulimic phase during their recoveries. Poor outcomes are associated with later age at onset of the eating disorder, longer duration of the illness, lower minimal weight [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/44\">",
"     44",
"    </a>",
"    ], and lower percent body fat after weight restoration [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/46\">",
"     46",
"    </a>",
"    ]. Overall, 32 to 70 percent recover fully at 20 years of follow-up; those who do not may have increased psychiatric comorbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/12,47,48\">",
"     12,47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Psychological variables are important predictors of outcome. In one four-year follow-up study, strong fears of maturing predicted a poor outcome in patients with restricting anorexia nervosa, while low self-esteem was associated with a poor outcome in those with bulimia nervosa [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/49\">",
"     49",
"    </a>",
"    ]. Significant items predicting better outcome in another report in patients with anorexia nervosa were insight and successful interpersonal relationships; mood and personality disorders were negative predictors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with anorexia nervosa who recover often suffer persisting psychiatric problems. In a case-control study of 70 female patients, those who no longer met criteria for anorexia nervosa still manifested relatively low body weight and cognitive features (perfectionism and cognitive restraint) of the disorder, as well as high rates of lifetime comorbid major depression, alcohol dependence, and anxiety disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H851987\">",
"    <span class=\"h2\">",
"     Bulimia nervosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study that followed 173 women with bulimia nervosa found that the number of patients who continued to meet the full criteria for bulimia nervosa declined as the duration of follow-up increased [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/52\">",
"     52",
"    </a>",
"    ]. However, recurrent binging and purging behaviors persisted over approximately 10 years of follow-up in 30 percent. Substance abuse and long duration of the disorder were associated with poor outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18369710\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies suggest that all cause mortality is elevated in patients with eating disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/53\">",
"     53",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H852824\">",
"    <span class=\"h2\">",
"     Anorexia nervosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anorexia nervosa appears to be associated with increased mortality:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 42 studies conducted between 1920 and 1980 (3,006 patients followed for a median of 8 years) found that all cause mortality was 0.56 percent per year [",
"      <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/54\">",
"       54",
"      </a>",
"      ]. Medical complications of anorexia nervosa accounted for approximately 50 percent of the deaths and suicide accounted for 25 percent. Heterogeneity was not reported.",
"     </li>",
"     <li>",
"      A review of four studies (660 patients) found that all cause mortality was 5 times the expected value (based upon general population mortality statistics), and suicide deaths were 32 times greater [",
"      <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/53\">",
"       53",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      A subsequent prospective study of 136 patients followed for a median of nine years found that all cause mortality was 12 times greater compared with the general population (standardized mortality ratio 11.6, 95% CI 5.5-21.3), and that completed suicide was 57 times greater in patients with anorexia nervosa (standardized mortality ratio 56.9, 95% CI 15.3-145.7) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/55\">",
"       55",
"      </a>",
"      ]. Duration of anorexia nervosa and severity of alcohol use disorder were associated with an increased risk of all cause mortality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, most mortality studies for anorexia nervosa were performed at referral centers that specialized in treatment resistant patients who were often hospitalized, and mortality rates may be lower outside of these centers. A retrospective community study examined mortality in 208 patients with relatively mild anorexia nervosa (most had never seen a psychiatrist and few had been hospitalized for the disorder) over a median follow-up of 22 years; all cause mortality for patients and for the general population were comparable (standardized mortality ratio 0.7, 95% CI 0.4-1.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/56\">",
"     56",
"    </a>",
"    ]. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H852860\">",
"    <span class=\"h2\">",
"     Bulimia nervosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bulimia nervosa may possibly be associated with increased mortality:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study of 906 patients who were followed for a mean of 19 years through the United States National Death Index found that all cause mortality was approximately twice as high, compared with the general population (standardized mortality ratio 1.6, 95% CI 1.1-2.2), and that the rate of suicide was approximately seven times greater (standardized mortality ratio 6.5, 95% CI 2.8-12.8) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/57\">",
"       57",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A retrospective study of 96 patients followed for 4 to 15 years found that all cause mortality was nine times the expected value [",
"      <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/53,58\">",
"       53,58",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, in a prospective study of 110 patients with bulimia nervosa, mortality for patients and mortality for the general population were comparable (standardized mortality ratio 1.3, 95% CI 0.0-7.2) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H852902\">",
"    <span class=\"h2\">",
"     Eating disorder not otherwise specified",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eating disorders not otherwise specified may be associated with increased mortality. A retrospective study of 802 patients with an eating disorder not otherwise specified, who were followed for a mean of 17 years through the United States National Death Index, found that all cause mortality was nearly twice as high compared with the general population (standardized mortality ratio 1.8, 95% CI 1.3-2.5), and that the rate of suicide was nearly four times greater (standardized mortality ratio 3.9, 95% CI 1.1-10.0) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23593/abstract/57\">",
"     57",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/16/25858?source=see_link\">",
"       \"Patient information: Anorexia nervosa (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/37/26194?source=see_link\">",
"       \"Patient information: Bulimia nervosa (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H260805661\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A DSM-IV-TR diagnosis of anorexia nervosa requires each of the criteria listed in the table (",
"      <a class=\"graphic graphic_table graphicRef75110 \" href=\"UTD.htm?9/7/9339\">",
"       table 1",
"      </a>",
"      ). The two subtypes of anorexia nervosa are restricting and binge",
"      <span class=\"nowrap\">",
"       eating/purging.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Anorexia nervosa'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/7/3194?source=see_link&amp;anchor=H173811834#H173811834\">",
"       \"Anorexia nervosa in adults: Diagnosis, associated clinical features, and assessment\", section on 'Diagnostic criteria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The DSM-IV-TR diagnostic criteria for bulimia nervosa include binge eating (consuming a large amount of food in a discrete period of time) and inappropriate compensatory behavior to prevent weight gain, both occurring on average at least two times per week for three months (",
"      <a class=\"graphic graphic_table graphicRef70006 \" href=\"UTD.htm?2/46/2796\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Bulimia nervosa'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33577?source=see_link&amp;anchor=H22668229#H22668229\">",
"       \"Bulimia nervosa in adults: Clinical features, diagnosis, and assessment\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In DSM-IV-TR, binge-eating disorder is characterized by episodes of eating an amount of food in a discrete period of time that is definitely larger than most people would eat in a similar period of time under similar circumstances. These episodes occur at least twice a week for at least six months. Episodes of binge eating are associated with a lack of control and with distress over the eating. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Binge-eating disorder'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34841?source=see_link\">",
"       \"Binge-eating disorder: Overview of treatment in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The estimated lifetime prevalence of anorexia nervosa in women is 0.9 and in men 0.3 percent. The estimated lifetime prevalence of bulimia nervosa in women is 1 to 1.5 percent. The estimated lifetime prevalence of binge-eating disorder in women is 3.5 and men 2.0 percent. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34841?source=see_link&amp;anchor=H103238672#H103238672\">",
"       \"Binge-eating disorder: Overview of treatment in adults\", section on 'Epidemiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is no consensus regarding the causes of eating disorders. A combination of genetic, biological, psychological, family, environmental, and social factors probably contribute to developing an eating disorder. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The SCOFF is a five-item self-report measure that screens for eating disorders. Other screening tools include the ESP, EAT, and Primary Care Evaluation of Mental Disorders Patient Health Questionnaire. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Screening tools'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients with anorexia nervosa and bulimia nervosa should be evaluated for medical complications. The evaluation should that include a history, physical examination, and laboratory testing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16550?source=see_link\">",
"       \"Anorexia nervosa in adults: Evaluation for medical complications and criteria for hospitalization to manage these complications\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33816?source=see_link&amp;anchor=H338058#H338058\">",
"       \"Bulimia nervosa and binge eating disorder in adults: Medical complications and their management\", section on 'Medical evaluation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44023?source=see_link&amp;anchor=H17#H17\">",
"       \"Eating disorders: Treatment\", section on 'Criteria for hospitalization'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Many medical complications can occur during starvation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      persistent purging. Complications of anorexia nervosa include myocardial atrophy, mitral valve prolapse, pericardial effusion, bradycardia, functional hypothalamic amenorrhea, antenatal and postpartum problems, osteoporosis, gastroparesis, and constipation (",
"      <a class=\"graphic graphic_table graphicRef67080 \" href=\"UTD.htm?29/44/30413\">",
"       table 5",
"      </a>",
"      ). Complications of bulimia nervosa include dehydration, hypokalemia, Mallory-Weiss syndrome, ipecac-induced myopathy, and erosion of dental enamel. Electrocardiogram changes can occur in both disorders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38890?source=see_link\">",
"       \"Anorexia nervosa in adults and adolescents: Medical complications and their management\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33816?source=see_link\">",
"       \"Bulimia nervosa and binge eating disorder in adults: Medical complications and their management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Approximately 50 percent of patients with anorexia nervosa have good outcomes (defined by return of menses and weight gain), 25 percent have intermediate outcomes, and 25 percent have a poor outcome. Outcome in bulimia nervosa is poor in approximately 30 percent. (See",
"      <a class=\"local\" href=\"#H18369703\">",
"       'Course of illness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All cause mortality appears to be elevated in eating disorders. Patients with anorexia nervosa frequently die from medical complications of the disorder or by suicide. (See",
"      <a class=\"local\" href=\"#H18369710\">",
"       'Mortality'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/2\">",
"      Wakeling A. Epidemiology of anorexia nervosa. Psychiatry Res 1996; 62:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/3\">",
"      Lucas AR, Beard CM, O'Fallon WM, Kurland LT. 50-year trends in the incidence of anorexia nervosa in Rochester, Minn.: a population-based study. Am J Psychiatry 1991; 148:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/4\">",
"      Heatherton TF, Nichols P, Mahamedi F, Keel P. Body weight, dieting, and eating disorder symptoms among college students, 1982 to 1992. Am J Psychiatry 1995; 152:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/5\">",
"      Hoek HW, van Hoeken D. Review of the prevalence and incidence of eating disorders. Int J Eat Disord 2003; 34:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/6\">",
"      Hudson JI, Hiripi E, Pope HG Jr, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry 2007; 61:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/7\">",
"      Keski-Rahkonen A, Hoek HW, Susser ES, et al. Epidemiology and course of anorexia nervosa in the community. Am J Psychiatry 2007; 164:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/8\">",
"      Fairburn CG, Beglin SJ. Studies of the epidemiology of bulimia nervosa. Am J Psychiatry 1990; 147:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/9\">",
"      Putukian M. The female triad. Eating disorders, amenorrhea, and osteoporosis. Med Clin North Am 1994; 78:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/10\">",
"      American Psychiatric Association. Treatment of patients with eating disorders,third edition. American Psychiatric Association. Am J Psychiatry 2006; 163:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/11\">",
"      Braun DL, Sunday SR, Huang A, Halmi KA. More males seek treatment for eating disorders. Int J Eat Disord 1999; 25:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/12\">",
"      Strober M, Freeman R, Morrell W. The long-term course of severe anorexia nervosa in adolescents: survival analysis of recovery, relapse, and outcome predictors over 10-15 years in a prospective study. Int J Eat Disord 1997; 22:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/13\">",
"      Strober M, Freeman R, Lampert C, et al. Males with anorexia nervosa: a controlled study of eating disorders in first-degree relatives. Int J Eat Disord 2001; 29:263.",
"     </a>",
"    </li>",
"    <li>",
"     Garner, DM, Garfinkel, PE. Handbook of treatment for eating disorders, 2nd ed, Guilford Press, New York 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/15\">",
"      Patton GC, Selzer R, Coffey C, et al. Onset of adolescent eating disorders: population based cohort study over 3 years. BMJ 1999; 318:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/16\">",
"      McKnight Investigators. Risk factors for the onset of eating disorders in adolescent girls: results of the McKnight longitudinal risk factor study. Am J Psychiatry 2003; 160:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/17\">",
"      Nattiv A, Agostini R, Drinkwater B, Yeager KK. The female athlete triad. The inter-relatedness of disordered eating, amenorrhea, and osteoporosis. Clin Sports Med 1994; 13:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/18\">",
"      Sanci L, Coffey C, Olsson C, et al. Childhood sexual abuse and eating disorders in females: findings from the Victorian Adolescent Health Cohort Study. Arch Pediatr Adolesc Med 2008; 162:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/19\">",
"      Woodside DB. A review of anorexia nervosa and bulimia nervosa. Curr Probl Pediatr 1995; 25:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/20\">",
"      Kendler KS, MacLean C, Neale M, et al. The genetic epidemiology of bulimia nervosa. Am J Psychiatry 1991; 148:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/21\">",
"      Strober M. Family-genetic studies of eating disorders. J Clin Psychiatry 1991; 52 Suppl:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/22\">",
"      Herzog DB, Nussbaum KM, Marmor AK. Comorbidity and outcome in eating disorders. Psychiatr Clin North Am 1996; 19:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/23\">",
"      Halmi KA, Eckert E, Marchi P, et al. Comorbidity of psychiatric diagnoses in anorexia nervosa. Arch Gen Psychiatry 1991; 48:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/24\">",
"      Bulik CM, Devlin B, Bacanu SA, et al. Significant linkage on chromosome 10p in families with bulimia nervosa. Am J Hum Genet 2003; 72:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/25\">",
"      Grice DE, Halmi KA, Fichter MM, et al. Evidence for a susceptibility gene for anorexia nervosa on chromosome 1. Am J Hum Genet 2002; 70:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/26\">",
"      Krug I, Treasure J, Anderluh M, et al. Present and lifetime comorbidity of tobacco, alcohol and drug use in eating disorders: a European multicenter study. Drug Alcohol Depend 2008; 97:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/27\">",
"      Anderluh MB, Tchanturia K, Rabe-Hesketh S, Treasure J. Childhood obsessive-compulsive personality traits in adult women with eating disorders: defining a broader eating disorder phenotype. Am J Psychiatry 2003; 160:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/28\">",
"      van Furth EF, van Strien DC, Martina LM, et al. Expressed emotion and the prediction of outcome in adolescent eating disorders. Int J Eat Disord 1996; 20:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/29\">",
"      Pirke KM. Central and peripheral noradrenalin regulation in eating disorders. Psychiatry Res 1996; 62:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/30\">",
"      Kaye WH. Persistent alterations in behavior and serotonin activity after recovery from anorexia and bulimia nervosa. Ann N Y Acad Sci 1997; 817:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/31\">",
"      Kaye WH, Gwirtsman HE, George DT, Ebert MH. Altered serotonin activity in anorexia nervosa after long-term weight restoration. Does elevated cerebrospinal fluid 5-hydroxyindoleacetic acid level correlate with rigid and obsessive behavior? Arch Gen Psychiatry 1991; 48:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/32\">",
"      Jean A, Conductier G, Manrique C, et al. Anorexia induced by activation of serotonin 5-HT4 receptors is mediated by increases in CART in the nucleus accumbens. Proc Natl Acad Sci U S A 2007; 104:16335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/33\">",
"      Katzman DK, Lambe EK, Mikulis DJ, et al. Cerebral gray matter and white matter volume deficits in adolescent girls with anorexia nervosa. J Pediatr 1996; 129:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/34\">",
"      Lambe EK, Katzman DK, Mikulis DJ, et al. Cerebral gray matter volume deficits after weight recovery from anorexia nervosa. Arch Gen Psychiatry 1997; 54:537.",
"     </a>",
"    </li>",
"    <li>",
"     Lowe, MR. Dietary restraint and overeating. In: Eating Disorders and Obesity, 2, Fairburn, CG, Browell, KD (Eds), The Guilford Press, New York 2002. p.88.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/36\">",
"      Morgan JF, Reid F, Lacey JH. The SCOFF questionnaire: assessment of a new screening tool for eating disorders. BMJ 1999; 319:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/37\">",
"      Cotton MA, Ball C, Robinson P. Four simple questions can help screen for eating disorders. J Gen Intern Med 2003; 18:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/38\">",
"      Hill LS, Reid F, Morgan JF, Lacey JH. SCOFF, the development of an eating disorder screening questionnaire. Int J Eat Disord 2010; 43:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/39\">",
"      Mintz LB, O'Halloran MS. The Eating Attitudes Test: validation with DSM-IV eating disorder criteria. J Pers Assess 2000; 74:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/40\">",
"      Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999; 282:1737.",
"     </a>",
"    </li>",
"    <li>",
"     Eating Disorders: Core Interventions in the Treatment of and Management of Anorexia Nervosa, Bulimia Nervosa and Related Eating Disorders. National Institute for Clinical Excellence, Clinical Guideline 9. file://guidance.nice.org.uk (Accessed on December 22, 2010).",
"    </li>",
"    <li>",
"     Mehler, PS, Birmingham, LC, Crow, SJ, Jahraus, JP. Medical complications of eating disorders. In: The Treatment of Eating Disorders: A Clinical Handbook, Grilo, CM, Mitchell, JE (Eds), The Guilford Press, New York 2010. p.66.",
"    </li>",
"    <li>",
"     Halmi, K. Eating disorders: Anorexia nervosa, bulimia nervosa, and obesity. In: The American Psychiatric Publishing Textbook of Psychiatry, Fifth Edition, Hales, RE, Yudofsky, SC, Gabbard GO (Eds), American Psychiatric Publishing, Inc., Washington, DC 2008. p.971.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/44\">",
"      Golden NH, Katzman DK, Kreipe RE, et al. Eating disorders in adolescents: position paper of the Society for Adolescent Medicine. J Adolesc Health 2003; 33:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/45\">",
"      Steinhausen HC. The outcome of anorexia nervosa in the 20th century. Am J Psychiatry 2002; 159:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/46\">",
"      Mayer LE, Roberto CA, Glasofer DR, et al. Does percent body fat predict outcome in anorexia nervosa? Am J Psychiatry 2007; 164:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/47\">",
"      Theander S. Outcome and prognosis in anorexia nervosa and bulimia: some results of previous investigations, compared with those of a Swedish long-term study. J Psychiatr Res 1985; 19:493.",
"     </a>",
"    </li>",
"    <li>",
"     Russell, GF. The prognosis of eating disorders, Springer-Verlag, New York 1991. p.198.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/49\">",
"      van der Ham T, van Strien DC, van Engeland H. Personality characteristics predict outcome of eating disorders in adolescents: a 4-year prospective study. Eur Child Adolesc Psychiatry 1998; 7:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/50\">",
"      Saccomani L, Savoini M, Cirrincione M, et al. Long-term outcome of children and adolescents with anorexia nervosa: study of comorbidity. J Psychosom Res 1998; 44:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/51\">",
"      Sullivan PF, Bulik CM, Fear JL, Pickering A. Outcome of anorexia nervosa: a case-control study. Am J Psychiatry 1998; 155:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/52\">",
"      Keel PK, Mitchell JE, Miller KB, et al. Long-term outcome of bulimia nervosa. Arch Gen Psychiatry 1999; 56:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/53\">",
"      Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry 1998; 173:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/54\">",
"      Sullivan PF. Mortality in anorexia nervosa. Am J Psychiatry 1995; 152:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/55\">",
"      Keel PK, Dorer DJ, Eddy KT, et al. Predictors of mortality in eating disorders. Arch Gen Psychiatry 2003; 60:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/56\">",
"      Kornd&ouml;rfer SR, Lucas AR, Suman VJ, et al. Long-term survival of patients with anorexia nervosa: a population-based study in Rochester, Minn. Mayo Clin Proc 2003; 78:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/57\">",
"      Crow SJ, Peterson CB, Swanson SA, et al. Increased mortality in bulimia nervosa and other eating disorders. Am J Psychiatry 2009; 166:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23593/abstract/58\">",
"      Patton GC. Mortality in eating disorders. Psychol Med 1988; 18:947.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2093 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-EC60C7DA3C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_2_23593=[""].join("\n");
var outline_f23_2_23593=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H260805661\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Anorexia nervosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Bulimia nervosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Eating disorder not otherwise specified",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Binge-eating disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Males with eating disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Role of the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PRESENTATION AND SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Anorexia nervosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Bulimia nervosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Screening tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MEDICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H260809155\">",
"      Anorexia nervosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H260809232\">",
"      Bulimia nervosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MEDICAL COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95585531\">",
"      Anorexia nervosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95585538\">",
"      Bulimia nervosa and binge eating disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18369703\">",
"      COURSE OF ILLNESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H851980\">",
"      Anorexia nervosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H851987\">",
"      Bulimia nervosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18369710\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H852824\">",
"      Anorexia nervosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H852860\">",
"      Bulimia nervosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H852902\">",
"      Eating disorder not otherwise specified",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H260805661\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/2093\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/2093|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/7/9339\" title=\"table 1\">",
"      DSM-IV-TR diagnostic criteria for anorexia nervosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/46/2796\" title=\"table 2\">",
"      DSM-IV-TR diagnostic criteria for bulimia nervosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/56/8079\" title=\"table 3\">",
"      Eating attitudes test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/32/22019\" title=\"table 4\">",
"      PHQ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/44/30413\" title=\"table 5\">",
"      Medical complications of anorexia nervosa",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36919?source=related_link\">",
"      Amenorrhea and infertility associated with exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38890?source=related_link\">",
"      Anorexia nervosa in adults and adolescents: Medical complications and their management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/16/30982?source=related_link\">",
"      Anorexia nervosa in adults and adolescents: The refeeding syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/7/3194?source=related_link\">",
"      Anorexia nervosa in adults: Diagnosis, associated clinical features, and assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16550?source=related_link\">",
"      Anorexia nervosa in adults: Evaluation for medical complications and criteria for hospitalization to manage these complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/28/8646?source=related_link\">",
"      Binge-eating disorder: Cognitive-behavioral therapy (CBT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34841?source=related_link\">",
"      Binge-eating disorder: Overview of treatment in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33816?source=related_link\">",
"      Bulimia nervosa and binge eating disorder in adults: Medical complications and their management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33577?source=related_link\">",
"      Bulimia nervosa in adults: Clinical features, diagnosis, and assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44023?source=related_link\">",
"      Eating disorders: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/16/25858?source=related_link\">",
"      Patient information: Anorexia nervosa (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/37/26194?source=related_link\">",
"      Patient information: Bulimia nervosa (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_2_23594="Sulfonamide allergy in non HIV-infected patients";
var content_f23_2_23594=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sulfonamide allergy in non HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/2/23594/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/2/23594/contributors\">",
"     Anthony Montanaro, MD, FAAAAI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/2/23594/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/2/23594/contributors\">",
"     N Franklin Adkinson, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/2/23594/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/2/23594/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/2/23594/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sulfonamide-containing antibiotics are the second most frequent cause of allergic drug reactions, after the beta-lactams (penicillins and cephalosporins). In one large study, the incidence of reactions to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) was 34 per 1000 patients exposed, compared to 51 per 1000 for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the adverse reactions caused by sulfonamides differ significantly from those attributed to beta-lactams, and the evaluation and management of sulfonamide reactions are distinct. The pathophysiology of allergic (or hypersensitivity) reactions to sulfonamides is complex and poorly understood.",
"   </p>",
"   <p>",
"    This topic review describes the most prevalent types of reactions to sulfonamides, the evaluation of patients with reported allergy, and cross-reactivity issues. Management options for patients with past reactions who require similar medications again are also presented. Most of the available literature concerns allergic reactions to antimicrobial sulfonamides, particularly TMP-SMX. However, reactions to non-antimicrobial sulfonamides (eg, diuretics, sulfonylureas, and others) and sulfones (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    ) will be briefly addressed as well.",
"   </p>",
"   <p>",
"    This review does not address the treatment of acute drug reactions. These are presented elsewhere, according to specific type of reaction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=see_link\">",
"     \"Drug eruptions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2456?source=see_link\">",
"     \"Drug fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The imprecise term \"sulfa drugs\" is most often applied to sulfonamide antimicrobials, although it is variably used for other medications as well. This term has contributed to ongoing confusion about relevant cross-reactivity among sulfonamide drugs. It is preferable to avoid \"sulfa allergy\" and instead document the specific medication that caused the adverse reaction and the symptoms that were involved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Types of sulfonamides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sulfonamide medications are drugs that contain a sulfonamide moiety (SO2NH2) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/2\">",
"     2",
"    </a>",
"    ]. There are two distinct groups of sulfonamides that differ in chemical structure as well as clinical use:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Antimicrobial sulfonamides",
"    </span>",
"    &nbsp;&mdash;&nbsp;This group includes sulfamethoxazole (in TMP-SMX) and other less commonly used antimicrobials (",
"    <a class=\"graphic graphic_table graphicRef82011 \" href=\"UTD.htm?2/49/2845\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/2\">",
"     2",
"    </a>",
"    ]. Antimicrobial sulfonamides contain an arylamine group (an amine group linked to a benzene ring). This moiety is attached to the sulfonamide group (",
"    <a class=\"graphic graphic_figure graphicRef61834 \" href=\"UTD.htm?38/11/39100\">",
"     figure 1",
"    </a>",
"    ). The presence of the arylamine moiety is believed central to the pathogenesis of hypersensitivity reactions, and only the antimicrobial sulfonamides contain it. These drugs also contain a substituted aromatic ring attached to the sulfonamide core (",
"    <a class=\"graphic graphic_figure graphicRef61834 \" href=\"UTD.htm?38/11/39100\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef59357 \" href=\"UTD.htm?8/60/9154\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Non-antimicrobial sulfonamides",
"    </span>",
"    &nbsp;&mdash;&nbsp;The agents in this group include diuretics, hypoglycemics, antiinflammatories, and antihypertensive agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"     sumatriptan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef57629 \" href=\"UTD.htm?31/8/31884\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/2\">",
"     2",
"    </a>",
"    ]. The non-antimicrobial sulfonamides do not contain an arylamine group or a substituted aromatic ring (",
"    <a class=\"graphic graphic_figure graphicRef59357 \" href=\"UTD.htm?8/60/9154\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Sulfones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sulfones are a distinct class of medications from sulfonamides.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     Dapsone",
"    </a>",
"    (diaminodiphenylsulphone) is the only sulfone in common clinical use (",
"    <a class=\"graphic graphic_figure graphicRef69968 \" href=\"UTD.htm?31/50/32557\">",
"     figure 3",
"    </a>",
"    ). Although dapsone is not a sulfonamide, it is included in this topic review because the hypersensitivity reactions reported to dapsone are clinically similar to those of sulfonamide antimicrobials, may have similar pathogenesis, and may have some cross-reactivity concerns as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Medications unrelated to sulfonamides",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following groups of medications are unrelated to sulfonamides, but are sometimes confused with them:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some medications contain sulfur atoms in their chemical structure, but do not contain specific sulfonamide or sulfone moieties. These include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"       captopril",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"       ranitidine",
"      </a>",
"      , and others [",
"      <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/3\">",
"       3",
"      </a>",
"      ]. There is no known cross-reactivity between these medications and sulfonamides.",
"     </li>",
"     <li>",
"      Another group of medications contains sulfate ions, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      sulfate. The sulfate moieties in these compounds are not a known source of allergic or immunologic issues.",
"     </li>",
"     <li>",
"      Finally, sulfites are chemicals used to preserve certain foods, beverages, and medications. Sulfites are associated with a distinct constellation of symptoms known as sulfite sensitivity, which is primarily mediated via non-immunologic mechanisms. Reactions to these latter medications and substances are reviewed separately. Sulfite sensitivity typically causes respiratory reactions in patients with asthma, but it is unrelated to sulfonamide hypersensitivity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40681?source=see_link\">",
"       \"Allergic and asthmatic reactions to food additives\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse reactions to TMP-SMX occurred in 8 percent of 1121 hospitalized patients receiving oral or parenteral treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/4\">",
"     4",
"    </a>",
"    ]. Women were affected twice as often as men. This study was published before the human immunodeficiency virus (HIV) epidemic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Impact of HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of sulfonamide reactions changed markedly with the appearance of HIV, as patients with this infection are markedly more susceptible to sulfonamide reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. However, this review focuses on sulfonamide allergy in patients without HIV infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TYPES OF HYPERSENSITIVITY REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of hypersensitivity reactions can occur in response to sulfonamide drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Isolated cutaneous reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common type of hypersensitivity reaction to sulfonamides is an isolated dermatologic reaction. Signs and symptoms are variable and may include erythema, maculopapular or morbilliform rash, urticaria, and pruritus. Most of these reactions appear within the first three days of therapy and resolve promptly after drug discontinuation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/4\">",
"     4",
"    </a>",
"    ]. The mechanisms responsible are unknown in most cases.",
"   </p>",
"   <p>",
"    The following should be noted, since cutaneous findings may be part of more serious types of reactions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of fever or any systemic symptoms should be assumed to represent the beginning of a more significant systemic reaction. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Morbilliform rash with fever and systemic symptoms'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Prominent urticaria or any other symptoms of an IgE-mediated reaction should take into consideration a possible immediate-type allergy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Immediate-type allergy and anaphylaxis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Morbilliform rash with fever and systemic symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;A more serious type of sulfonamide hypersensitivity is characterized by a pruritic, maculopapular or morbilliform rash, accompanied or preceded by fever. In some patients, this progresses to multi-system organ involvement and dysfunction. Severity can range from mild to severe to fatal. Sulfonamide antimicrobials (usually TMP-SMX) are most commonly implicated in this type of reaction, although non-antimicrobial sulfonamides are occasionally causative.",
"   </p>",
"   <p>",
"    Symptoms generally develop one to two weeks after the start of administration, with fever usually appearing first, sometimes accompanied by malaise and pharyngitis. Peripheral blood smear may reveal an atypical lymphocytosis or eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. Organ involvement may be asymptomatic or overt, and can include hepatitis, nephritis, pulmonary infiltrates, and cytopenias. Symptoms generally resolve one to two weeks after discontinuation. With reexposure, symptoms may appear within one to two days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Immediate-type allergy and anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sulfonamide antimicrobials can cause type I, or immediate-type hypersensitivity reactions, although this is not common [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/8\">",
"     8",
"    </a>",
"    ]. Type I reactions are mediated primarily by specific IgE antibodies, which trigger sensitized mast cells (and basophils) to degranulate, releasing histamine and other vasoactive mediators (",
"    <a class=\"graphic graphic_table graphicRef80466 \" href=\"UTD.htm?13/11/13500\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Typical symptoms include urticaria, angioedema, bronchospasm, laryngeal edema, and hypotension.",
"   </p>",
"   <p>",
"    There is some evidence that these rare reactions involve the substituted aromatic ring, rather than the arylamine portion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/11\">",
"     11",
"    </a>",
"    ]. Non-antimicrobial sulfonamides have also been implicated but not convincingly documented [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For sulfonamides, the relevant drug antigen is usually not the intact drug itself. Instead, reactive metabolites may become bound in large numbers to serum or cell-surface carrier proteins and thereby create a multivalent immunologic stimulus, which can differ structurally from the parent drug. Thus, the utility of skin testing with the original (unmetabolized) sulfonamide is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Stevens-Johnson syndrome and toxic epidermal necrolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial sulfonamides are strongly associated with Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN, or Lyell syndrome). In contrast, the non-antimicrobial sulfonamides (including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    , thiazide diuretics, and sulfonylurea hypoglycemics) are not associated with an excess risk of",
"    <span class=\"nowrap\">",
"     SJS/TEN",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SJS is characterized by a prodrome of malaise and fever, followed by the rapid onset of erythematous or purpuric macules and plaques and blistering of the mucous membranes. The skin lesions progress to epidermal necrosis and sloughing. TEN, or Lyell's syndrome, is a similar but more severe disorder that involves a greater percentage of the body surface area.",
"   </p>",
"   <p>",
"    The immunologic mechanisms of",
"    <span class=\"nowrap\">",
"     SJS/TEN",
"    </span>",
"    remain enigmatic. These disorders are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Erythema multiforme (EM) is a milder cutaneous reaction consisting of target and vesiculobullous lesions involving the mucosal membranes and favoring the extremities (and palms and soles). SJS and severe erythema multiforme (EM) are viewed by many experts, although not all, as separate entities. EM has also been reported in association with sulfonamide antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=see_link\">",
"     \"Drug eruptions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other uncommon reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sulfonamide drugs, usually the antimicrobials, are infrequently associated with several other types of reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Serum sickness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum sickness, a type III immunologic reaction, is occasionally caused by sulfonamide antimicrobials (",
"    <a class=\"graphic graphic_table graphicRef80466 \" href=\"UTD.htm?13/11/13500\">",
"     table 3",
"    </a>",
"    ). These reactions present approximately 10 days to 2 weeks after initiation of therapy, with fever, rash (which is often urticarial), arthralgia, and lymphadenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/16\">",
"     16",
"    </a>",
"    ]. Serum sickness is a self-limited response following discontinuation of the drug. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8842?source=see_link\">",
"     \"Serum sickness and serum sickness-like reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Hemolytic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucose-6-phosphate dehydrogenase (G6PD) deficiency is generally considered a contraindication to the use of sulfonamide drugs, as these agents can cause hemolytic anemia. This is a genetic metabolic-type adverse drug reaction rather than an immunologic reaction. The different sulfonamides vary in their risk of causing hemolysis in patients with G6PD deficiency. Several of the antimicrobials are considered high risk (",
"    <a class=\"graphic graphic_table graphicRef82011 \" href=\"UTD.htm?2/49/2845\">",
"     table 1",
"    </a>",
"    ), whereas few of the non-antimicrobials are.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/18/37157?source=see_link\">",
"     Probenecid",
"    </a>",
"    is one exception that is considered high risk (",
"    <a class=\"graphic graphic_table graphicRef57629 \" href=\"UTD.htm?31/8/31884\">",
"     table 2",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     Dapsone",
"    </a>",
"    also carries significant risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=see_link\">",
"     \"Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of the most prevalent type of sulfonamide hypersensitivity reaction (ie, fever and non-exfoliative rash) has not been conclusively defined and is likely multifactorial [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/3,7,17\">",
"     3,7,17",
"    </a>",
"    ]. Metabolism of sulfonamide antimicrobials results in intermediate forms of the drug that are believed to be critical in the pathogenesis of some reactions, although interactions between unmetabolized sulfonamide antimicrobials and T cell receptors have also been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/18\">",
"     18",
"    </a>",
"    ]. It is unclear if the mechanisms described herein are involved in fever and non-exfoliative rash only, or also in",
"    <span class=\"nowrap\">",
"     SJS/TEN,",
"    </span>",
"    although cytotoxic mechanisms are likely more prominent in",
"    <span class=\"nowrap\">",
"     SJS/TEN.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38456?source=see_link&amp;anchor=H7#H7\">",
"     \"Drug allergy: Pathogenesis\", section on 'Pharmacological interaction of drugs with immune receptors (the p-i concept)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Sulfonamide metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sulfonamide antimicrobials are metabolized along several pathways. Some of the drug becomes acetylated (via N-acetyl transferase) at the arylamine moiety to form non-toxic metabolites that are excreted in the urine. Alternatively, the arylamine group may undergo N-oxidation via cytochrome P450 to form reactive metabolites (",
"    <a class=\"graphic graphic_figure graphicRef72628 \" href=\"UTD.htm?30/17/31006\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/17,19\">",
"     17,19",
"    </a>",
"    ]. These reactive metabolites can act as haptens, or small molecules that become covalently linked to large host proteins. These hapten-protein complexes may be recognized as foreign and initiate an immunologic reaction. Other intermediate metabolites may be directly cytotoxic [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/17,19\">",
"     17,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors that slow metabolism, such as slow acetylation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    glutathione deficiency states (such as HIV infection), may increase exposure to these metabolites and thus enhance the likelihood of hypersensitivity reactions (",
"    <a class=\"graphic graphic_figure graphicRef72628 \" href=\"UTD.htm?30/17/31006\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13754?source=see_link\">",
"     \"Drugs and the liver: Metabolism and mechanisms of injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     CROSS-REACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is minimal evidence of cross-reactivity between sulfonamide antimicrobials and non-antimicrobials. However, the available information about cross-reactivity between these two groups is limited to observational studies, as there are no validated skin tests or serologic tests to diagnose or confirm sulfonamide allergy. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Evaluation and diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Confounding in studies of cross-reactivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of cross-reactivity among related medications are often confounded by the fact that a clinical history of drug allergy, by itself, identifies a subgroup of patients who are at increased risk of reactions to medications in general, even in the absence of actual cross-reactivity among the implicated drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/21\">",
"     21",
"    </a>",
"    ]. Patients with immunologic reactions to two or more chemically distinct types of drugs are said to have \"multiple drug allergy syndrome,\" although the exact definition of this syndrome is evolving, as discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24554?source=see_link\">",
"     \"An approach to the patient with drug allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The propensity of certain patients to develop drug reactions was demonstrated in a large, retrospective cohort study performed on a medical database of over eight million patients spanning a 12 year period [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/22\">",
"     22",
"    </a>",
"    ]. Individuals who had a documented allergic reaction to a sulfonamide antibiotic in the past did indeed react more commonly to a sulfonamide non-antibiotic (10 percent) compared to those who tolerated sulfonamide antibiotics (1.6 percent). However, those same individuals with documented sulfonamide antibiotic reactions reacted to the chemically distinct penicillins even more often (14 percent). In addition, there was a higher risk of reaction to sulfonamide non-antibiotics in those with a history of reactions to penicillins than those with a history of reactions to sulfonamide antibiotics.",
"   </p>",
"   <p>",
"    This strongly suggests that a predisposition of drug hypersensitivity reactions, in general, is a better predictor for sulfonamide allergy, than a past reaction to a different type of sulfonamide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Between sulfonamide antimicrobials and non-antimicrobials",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is minimal evidence of cross-reactivity between sulfonamide antimicrobials and non-antimicrobials (",
"    <a class=\"graphic graphic_table graphicRef82011 \" href=\"UTD.htm?2/49/2845\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef57629 \" href=\"UTD.htm?31/8/31884\">",
"     table 2",
"    </a>",
"    ). The strongest data in support of this statement is the large database study described in the preceding section [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Confounding in studies of cross-reactivity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other evidence includes small studies and series demonstrating that most, although not all, patients with a history of reacting to an antimicrobial sulfonamide will tolerate non-antimicrobial sulfonamides [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/7,8,22,23\">",
"     7,8,22,23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective observational study of 94 hospitalized adults with reported \"sulfa allergy\" noted that 40 patients had taken a non-antimicrobial sulfonamide, most often",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      , as outpatients for a median duration of 6.2 years, and nine patients had received non-antimicrobial sulfonamides as inpatients, all without adverse reactions [",
"      <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective series described 34 patients with reported \"sulfa allergy\" who were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"       acetazolamide",
"      </a>",
"      (non-antimicrobial sulfonamides) for intracranial hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/23\">",
"       23",
"      </a>",
"      ]. There were no reactions in those who received furosemide. Urticaria developed in two patients treated with acetazolamide, although no patients experienced severe reactions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the available evidence does not support the existence of cross-reactivity between the two sulfonamide groups. Despite this, the United States Food and Drug Administration (FDA)-approved product information for many non-antimicrobial sulfonamide drugs contains warnings concerning possible cross-reactions (",
"    <a class=\"graphic graphic_table graphicRef57629 \" href=\"UTD.htm?31/8/31884\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A data synthesis of the cases of suspected cross-reactions, including published reports and manufacturers' data on file from 1966 to 2004, noted that the FDA product information for 17 of 33 non-antimicrobial sulfonamide drugs included varying statements, warnings, or actual contraindication statements against their use in patients with \"sulfonamide\" allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/24\">",
"     24",
"    </a>",
"    ]. The authors of this analysis concluded that, when subjected to closer examination, these data did not establish a reasonable probability of immunologic or hypersensitivity syndrome cross-reactivity between the two sulfonamide groups [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/24\">",
"     24",
"    </a>",
"    ]. We agree with this conclusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Celecoxib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cross-reactivity between antimicrobial sulfonamides and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    (a non-arylamine sulfonamide) has not been adequately analyzed. However, in keeping with the general lack of cross-reactivity between the antimicrobial and non-antimicrobial sulfonamides, the bulk of evidence to date suggests that cross-reactivity is unlikely [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective pilot study of 28 patients with a history of reactions to antimicrobial sulfonamides were challenged with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      , initially with a small test dose and followed by a full dose, after extensive allergy evaluation [",
"      <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/25\">",
"       25",
"      </a>",
"      ]. None experienced allergic reactions.",
"     </li>",
"     <li>",
"      In a large meta-analysis of over 11,000 patients from 14 double-blinded trials of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      used for arthritis, the rate of allergic reactions specifically to celecoxib was not statistically different from placebo or active alternate therapy (other nonsteroidal antiinflammatory drugs, NSAIDs) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/26\">",
"       26",
"      </a>",
"      ]. Although sulfonamide hypersensitivity was part of the exclusion criteria for those trials, 135 patients were included despite histories of sulfonamide hypersensitivity. Subgroup analysis of those patients did reveal a higher rate of dermatologic reactions compared to the group as a whole. However, the three- to sixfold elevation in rate of reactions was also seen in patients receiving other NSAIDs and placebo, indicating that these patients were at higher risk for hypersensitivity drug reactions in general [",
"      <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/26\">",
"       26",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      However, there are separate concerns about celecoxib and an increased incidence of Stevens-Johnson syndrome (SJS). A large retrospective review of post-marketing safety surveillance reports (from the United States Food and Drug Administration Adverse Events Reporting System) for several of the selective COX-2 inhibitors documented significant increases of reported SJS above baseline rates [",
"      <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/27\">",
"       27",
"      </a>",
"      ]. Compared with an expected background rate of 1.9 cases per million annually, calculated rates were 5.7 per million in celecoxib users (based on 19 reported cases in the first two years of marketing). Twenty-one percent of these individuals had also reported \"sulfa allergy.\" Since comparison data from appropriate control groups are not available in studies of this nature, risks of possible cross-reactivity cannot be calculated or directly inferred. However, further studies are needed to define the risk of SJS with celecoxib.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, there are few data to support cross-reactivity between sulfonamide antimicrobials and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    , although celecoxib may be independently associated with an increased rate of SJS. Until more information is available, we would consider the use of celecoxib in patients with past sulfonamide cutaneous reactions that were mild, although we would avoid celecoxib in a patient with past fever to sulfonamides. Because of the possible association between celecoxib and SJS, we would probably avoid celecoxib in a patient with past exfoliative reactions to any medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Between sulfonamide antimicrobials and dapsone",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    is a sulfone, not a sulfonamide. However, hypersensitivity to dapsone (or the \"sulfone syndrome\") is characterized by symptoms similar to those seen in sulfonamide reactions (such as fever and rash, sometimes accompanied by hepatitis, lymphadenopathy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hemolytic anemia), and it can be even more severe [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. It is currently unclear if there is cross-reactivity between sulfones and sulfonamide antimicrobials, but it seems prudent to avoid both types of agents whenever possible in patients who have had serious reactions (eg,",
"    <span class=\"nowrap\">",
"     SJS/TEN,",
"    </span>",
"    rash with fever and systemic symptoms, serum sickness, or hemolytic anemia) to one or the other.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Among non-antimicrobial sulfonamides",
"    </span>",
"    &nbsp;&mdash;&nbsp;The non-antimicrobial sulfonamides have been associated with far fewer immunologic reactions. Information about cross-reactivity among various agents within this class is derived from case reports, and the paucity of such reports suggests that cross-sensitivity is very low [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/12,32\">",
"     12,32",
"    </a>",
"    ]. Thus, when justified by clinical need, a patient with a past non-anaphylactic reaction to a non-antimicrobial sulfonamide can receive a different non-antimicrobial sulfonamide using a graded challenge protocol. (See",
"    <a class=\"local\" href=\"#H36\">",
"     'Needing a sulfonamide from the same group'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough and detailed history is the most important component of the evaluation of a patient who reports sulfonamide allergy because there are no definitive in vivo or in vitro tests for either confirming or excluding the allergy to these medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general approach to information gathering in a patient with possible drug allergy (eg, clinical history and review of records) is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24554?source=see_link\">",
"     \"An approach to the patient with drug allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary goals in taking a history about past reactions to sulfonamides are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessing what type of reaction the patient likely experienced in the past. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Types of hypersensitivity reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Assuring that the reaction was not suggestive of severe forms of hypersensitivity, such as",
"      <span class=\"nowrap\">",
"       SJS/TEN",
"      </span>",
"      or anaphylaxis. Accordingly, patients who report emergency department visits or hospitalizations, blistering or peeling of the skin or mucous membranes, or use specific phrases such as \"anaphylaxis\" or \"nearly died,\" in association with prior sulfonamide reactions, must be taken very seriously [",
"      <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consultation with an allergy specialist experienced in adverse drug reactions is recommended if retreatment with any type of sulfonamide is being considered in a patient with a significant or multi-system reaction to a sulfonamide in the past or who cannot provide much information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are currently no reliable, valid, and practical testing techniques to evaluate patients with past sulfonamide reactions, although a variety of immunologic testing techniques have been tried experimentally, including in vivo tests such as skin testing and patch testing, as well as in vitro tests such as lymphocyte toxicity assays, ELISA, RAST, and drug-specific IgG and IgE testing [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/33-38\">",
"     33-38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Trimethoprim allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subset of patients who react to a TMP-SMX combination product are sensitive to the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    component. This has mostly been documented in HIV-infected patients, in whom up to 20 percent of reactions were due to trimethoprim allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. However, both generalized erythematous skin eruptions and fixed drug eruption in response to trimethoprim have been reported in patients without HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. Careful graded challenge with trimethoprim is often required to clarify the situation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of the most common forms of sulfonamide allergy, ie, simple rash and rash with fever, are made clinically [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Morbilliform rash with fever and systemic symptoms'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    SJS and TEN are also clinical diagnoses supported by compatible histologic findings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link&amp;anchor=H27#H27\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\", section on 'Evaluation and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues surrounding the diagnosis of other types of allergic reactions to sulfonamides are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8842?source=see_link\">",
"     \"Serum sickness and serum sickness-like reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     FUTURE USE OF SULFONAMIDES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     General strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three general approaches to the future use of sulfonamide drugs in patients with past reactions to a specific agent: avoidance, test dosing to confirm lack of allergy, and desensitization if allergy is likely [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/46\">",
"     46",
"    </a>",
"    ]. The choice of strategy depends upon the type and severity of the past reaction, and on the risks and benefits of alternative treatments. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Patients with previous morbilliform rash (+/- fever)'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H37\">",
"     'Patients with previous SJS or TEN'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Avoidance",
"      </strong>",
"      &mdash; Use of an alternative medication of a distinct pharmacologic class is obviously the safest and simplest option in most patients with past sulfonamide reactions. Avoidance is the only safe approach if a patient describes symptoms consistent with any type of exfoliative dermatitis or diffuse erythroderma. These patients should almost never undergo test dosing or desensitization, except in very unusual circumstances. Case series have noted that SJS and TEN can recur and may be more severe with even minor reexposures [",
"      <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Test dosing",
"      </strong>",
"      &mdash; Test dosing (or graded drug challenge) is a term used to describe the cautious administration of small and increasing doses of a medication under medical observation. Test dosing is appropriate for patients who are UNLIKELY to be allergic to the drug in question. It does not alter the patient's immune response to the drug, so patients who tolerate a graded challenge prove that they are not allergic to that drug.",
"      <br/>",
"      <br/>",
"      The starting dose used is influenced by the severity and remoteness of the past reaction, and may range from",
"      <span class=\"nowrap\">",
"       1/1000",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       1/10",
"      </span>",
"      of the therapeutic dose [",
"      <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/46,48\">",
"       46,48",
"      </a>",
"      ]. This amount is then gradually increased by 3- to 10-fold at each step. The steps are administered at time intervals that are long enough to allow for the development of symptoms, and these intervals are determined by the nature of the past reaction.",
"      <br/>",
"      <br/>",
"      As an example, a patient who had previously developed a maculopapular rash in response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      and now required",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/6/29800?source=see_link\">",
"       glyburide",
"      </a>",
"      would be an appropriate candidate for test dosing, as cross-sensitivity between these two non-antimicrobial sulfonamides is unlikely, but not impossible. If the patient reports that the rash to hydrochlorothiazide had appeared within two to four hours of the last administered dose, then it would be appropriate to give test doses at intervals of six to eight hours, beginning at one-tenth of the target dose. In this example, a relatively large initial dose is acceptable, because the original reaction to hydrochlorothiazide was not severe.",
"     </li>",
"     <li>",
"      <strong>",
"       Desensitization",
"      </strong>",
"      &mdash; The term desensitization is used to describe the cautious administration of small and increasing doses of a medication under careful medical observation to patients who are LIKELY to be allergic to the drug in question. Desensitization alters the patient's underlying response to the drug, although only temporarily, as long as there is uninterrupted exposure to the medication. Desensitization is appropriate when there are no acceptable alternative medications. Desensitization is most often used in patients with IgE-mediated, type I hypersensitivity reactions, although in the case of sulfonamide drugs, protocols have been developed for use in patients with the more common presentation of rash and fever. (See",
"      <a class=\"local\" href=\"#H40\">",
"       'Desensitization'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27348531\">",
"    <span class=\"h2\">",
"     Precautions with any form of reexposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consultation with an allergy specialist experienced in adverse drug reactions is recommended if either test dosing or desensitization are under consideration, unless the clinician is specifically experienced with these procedures. Precautions regarding both test dosing and desensitization include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      These procedures are performed immediately before required treatment.",
"     </li>",
"     <li>",
"      Medications are administered without premedication, which could obscure detection of early and mild allergic symptoms.",
"     </li>",
"     <li>",
"      Documentation of informed consent, including a thorough discussion of risks and benefits of the procedure, is essential.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Patients with previous morbilliform rash (+/- fever)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most patients with fever and non-blistering rash in response to a sulfonamide drug in the past, the use of chemically distinct medication is the most prudent option. However, if there is no equivalent alternative medication and another sulfonamide medication is required, then both test dosing and desensitization may be considered. These situations require clinical judgment and clear communication with the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Needing a sulfonamide from a different group",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is minimal evidence for cross-reactivity between sulfonamides antimicrobials and non-antimicrobials, as previously discussed. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Cross-reactivity'",
"    </a>",
"    above.) Thus, for patients requiring a drug from the other group (eg, a patient requiring",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    who had a past rash and fever to TMP-SMX), there are two options for treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Simply give the drug normally: This is appropriate in a patient who does NOT have multiple drug allergies and whose past reaction to the sulfonamide from the other group was limited to morbilliform rash, or rash and fever.",
"     </li>",
"     <li>",
"      Administration of one or more test doses of the desired drug: This is our preferred approach for the patient with multiple drug allergies, as this clinical history identifies a subset of patients at higher risk for drug reactions in general. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Confounding in studies of cross-reactivity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The specific test dose protocol would be based upon the patient's past reaction. If the original reaction involved delayed-onset rash, initial test doses can be repeated for several days without dose escalation in order to ensure that any reactions have sufficient time to develop. As an example, a patient with past hypersensitivity to TMP-SMX who required",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    could take one-half of the lowest strength tablet available, once daily for a week, as an initial test dose. Even lower initial test doses can be obtained by diluting commercially-available oral solutions. If no symptoms developed, then the patient could be advanced stepwise to the full therapeutic dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Needing a sulfonamide from the same group",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several potential clinical scenarios that may arise in which a patient with a past sulfonamide reaction requires an agent from the same group of sulfonamides, and no equivalent alternative drug can be identified.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       TMP-SMX allergy in a patient needing TMP-SMX again",
"      </strong>",
"      &mdash; Desensitization is appropriate in this setting. Desensitization to TMP-SMX is best studied in HIV-infected patients, although the authors and editors have performed TMP-SMX desensitization in non HIV-infected patients with similar success. (See",
"      <a class=\"local\" href=\"#H40\">",
"       'Desensitization'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Sulfonamide diuretic allergy in a patient needing diuresis",
"      </strong>",
"      &mdash; Most of the potent loop diuretics (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/9/43158?source=see_link\">",
"       bumetanide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/13/28886?source=see_link\">",
"       torsemide",
"      </a>",
"      ) and other diuretics (including thiazides, and carbonic anhydrase inhibitors, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"       acetazolamide",
"      </a>",
"      ) are sulfonamides. These drugs may cause allergic reactions, as discussed previously, albeit less commonly than the antimicrobial sulfonamides [",
"      <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/49\">",
"       49",
"      </a>",
"      ]. The risk of cross-reactivity among them is poorly understood, although there has been a presumption of cross-reactivity among the thiazide diuretics, supported by case reports.",
"      <br/>",
"      <br/>",
"      Presently,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/10/7334?source=see_link\">",
"       ethacrynic acid",
"      </a>",
"      is the only available loop diuretic with no known potential to cross-react with sulfonamide-containing diuretics [",
"      <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/50\">",
"       50",
"      </a>",
"      ]. It is therefore the preferred agent for an individual who previously reacted to a sulfonamide-containing diuretic and requires diuresis again.",
"      <br/>",
"      <br/>",
"      Desensitization to one of the sulfonamide diuretics is useful if ethacrynic acid is unavailable or insufficiently effective. There have been published reports of successful graded-dose challenges to torsemide and desensitizations to furosemide in patients with previous reactions to sulfonamide diuretics [",
"      <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/49,51\">",
"       49,51",
"      </a>",
"      ]. Together, these reports describe three cases: One patient's initial reaction to sulfonamide diuretics was diffuse hives without other signs of anaphylaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/49\">",
"       49",
"      </a>",
"      ], a second had pancytopenia [",
"      <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/49\">",
"       49",
"      </a>",
"      ], and a third had recurrent pancreatitis with furosemide, bumetanide, and torsemide [",
"      <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/51\">",
"       51",
"      </a>",
"      ]. Sulfonamide diuretics were successfully reintroduced to all three patients.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       Sulfasalazine",
"      </a>",
"      <strong>",
"       allergy in inflammatory diseases",
"      </strong>",
"      &mdash; Sulfasalazine is a pro-drug that is converted into 5-ASA and sulfapyridine (an arylamine sulfonamide) following oral administration (",
"      <a class=\"graphic graphic_table graphicRef79777 \" href=\"UTD.htm?17/59/18363\">",
"       table 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef59357 \" href=\"UTD.htm?8/60/9154\">",
"       figure 2",
"      </a>",
"      ). It is used in the treatment of inflammatory bowel disease, psoriasis, lupus, and rheumatoid arthritis. A history of sulfonamide hypersensitivity reactions frequently complicated the management of these conditions in the past, although newer preparations of 5-ASA, which are not sulfonamides (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       mesalamine",
"      </a>",
"      ), and other immunomodulatory therapies have become available [",
"      <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/52\">",
"       52",
"      </a>",
"      ]. However, prior to these new therapies, relatively successful protocols for sulfasalazine reintroduction were published [",
"      <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/53-56\">",
"       53-56",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=see_link\">",
"       \"Management of severe ulcerative colitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Sulfonylurea allergy in diabetes",
"      </strong>",
"      &mdash; Some oral hypoglycemic agents used in the management of type II diabetes mellitus are non-antimicrobial sulfonamides, known as sulfonylurea agents. These include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/6/29800?source=see_link\">",
"       glyburide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/28/40391?source=see_link\">",
"       glipizide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8823?source=see_link\">",
"       glimepiride",
"      </a>",
"      , and a few other insulin secretagogues that are no longer commonly used (",
"      <a class=\"graphic graphic_table graphicRef57629 \" href=\"UTD.htm?31/8/31884\">",
"       table 2",
"      </a>",
"      ). Sulfonylureas occasionally cause adverse reactions with presumed immunologic mechanisms, most commonly dermatologic reactions such as urticaria, photosensitive rash, and leukocytoclastic vasculitis. There is little in the published medical literature addressing issues of possible cross-reactivity between sulfonylureas and other sulfonamides, but these is some evidence of patterns of cross-allergenicity within the sulfonylurea group itself [",
"      <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/12\">",
"       12",
"      </a>",
"      ]. Thus, the patient is best managed with an unrelated, non-sulfonamide medication.",
"      <br/>",
"      <br/>",
"      The issue of sulfonylurea allergy has become less of a concern over time, as numerous other agents of different classes and mechanisms have been developed for the management of diabetes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link\">",
"       \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Patients with previous SJS or TEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed previously, exfoliative rashes include SJS and TEN. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reexposure to the culprit drug or a sulfonamide in the same group is CONTRAINDICATED if a patient describes symptoms consistent with an exfoliative dermatitis or diffuse erythroderma. This contraindication applies to both test dosing and desensitization. Case series have noted that SJS and TEN can recur with even minor reexposures and may be more severe the second time [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Needing a sulfonamide from a different group",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our practice is to avoid all sulfonamides and sulfones in patients with past SJS or TEN. However, rare situations may arise in which a sulfonamide from a different group is needed for a life-threatening condition. Consultation with an allergy specialist experienced in adverse drug reactions would be essential in this setting. One report described successful reintroduction of a sulfonamide diuretic in a patient with SJS to",
"    <span class=\"nowrap\">",
"     TMP/SMX",
"    </span>",
"    years earlier and uncomplicated rashes with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/50\">",
"     50",
"    </a>",
"    ]. He was treated for several years with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/10/7334?source=see_link\">",
"     ethacrynic acid",
"    </a>",
"    , but this drug then became temporarily unavailable and his heart failure progressed. After giving informed consent, the patient received a graded challenge using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/13/28886?source=see_link\">",
"     torsemide",
"    </a>",
"    , which was chosen because it was structurally more different from furosemide, compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/9/43158?source=see_link\">",
"     bumetanide",
"    </a>",
"    . He was initially given torsemide 2.5 mg daily for one week. The dose was then increased to 10 mg daily over the next six weeks. He did not diurese adequately at this dose, so the dose was increased to 40 mg daily over the ensuing month. The patient developed no allergic symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Patients with past anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with past reactions consistent with IgE-mediated allergy or anaphylaxis (ie, hives, angioedema, bronchospasm, laryngeal edema,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypotension), the causative drug should be avoided. In addition, all sulfonamides within the same group should also be avoided. As an example, a patient who experienced apparent anaphylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    should not be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    or other sulfonamide diuretics. If such therapy is essential, then a desensitization protocol designed for type I, IgE-mediated allergy should be employed under the guidance of an allergy specialist. (See",
"    <a class=\"local\" href=\"#H40\">",
"     'Desensitization'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     DESENSITIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term desensitization is used to describe the cautious administration of small and increasing doses of a medication under careful medical observation to patients in whom allergic reactions are considered PROBABLE. Desensitization may be attempted for some types of reactions when there are no medically acceptable alternatives.",
"   </p>",
"   <p>",
"    The term desensitization usually refers to procedures designed to allow patients with a history of Type I (IgE-mediated, immediate type hypersensitivity) drug allergy to TEMPORARILY tolerate readministration of a medication, such as penicillin [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/20\">",
"     20",
"    </a>",
"    ]. Patients must continue to take the medication regularly (usually at least daily) following a successful desensitization procedure. Because of the temporary nature of the effect, the term \"hyposensitization\" is preferred by some allergy experts.",
"   </p>",
"   <p>",
"    Protocols have also been developed for a small number of other medication reactions that result from non-IgE mediated immunologic mechanisms, including sulfonamide sensitivity involving delayed maculopapular rashes and fever. Unfortunately, these procedures for non-IgE mediated skin rashes are also called desensitizations, despite the lack of evidence that any immune cell (eg, T lymphocyte) is downregulated as a result of the process. Despite these uncertainties, desensitization is the commonly-used term for sulfonamide reexposure protocols, and this review uses the term as well. These protocols may appear to be successful in large part because many patients lose immunologic sensitivity over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Protocols for past rash/fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;The protocols described in this section are intended to be performed in patients with past morbilliform rash with or without fever, for whom there is no equivalent alternative treatment.",
"   </p>",
"   <p>",
"    Drug desensitization protocols vary, although all are based upon administering increasing doses of medication in an uninterrupted and stepwise manner, beginning with very low doses. The protocols presented here have been performed successfully by the author, although modifications may be made based on characteristics of the individual case. In most cases, these modifications are made to escalate the dose more slowly. Clinicians should avoid altering successful protocols to render them faster or significantly change the time interval between doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Trimethoprim-sulfamethoxazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a significant number of published desensitization protocols for use in HIV-positive patients requiring TMP-SMX, 11 of which were compared in detail in a review on drug desensitization [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/20\">",
"     20",
"    </a>",
"    ]. The efficacy of these protocols has not been compared in head-to-head studies and the optimal approach has not been determined. Most of the published TMP-SMX desensitization trials have used the oral route, as this is presumed safer than intravenous administration.",
"   </p>",
"   <p>",
"    Two prospective trials of TMP-SMX desensitization are presented in detail here [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/37,57\">",
"     37,57",
"    </a>",
"    ]. Both were performed in HIV-positive patients who required PCP prophylaxis and had a history of TMP-SMX associated fever or non-exfoliative skin rash. We have used these two protocols successfully in our clinic and have used them successfully in patients without HIV infection, with no apparent differences in outcome.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest published study of TMP-SMX desensitization in HIV-positive patients involved 48 patients undergoing the protocol outlined in the table (",
"      <a class=\"graphic graphic_table graphicRef70864 \" href=\"UTD.htm?14/58/15276\">",
"       table 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/57\">",
"       57",
"      </a>",
"      ]. By day three, subjects were receiving a full (single strength) TMP-SMX tablet, and 77 percent of those undergoing this regimen were able to tolerate the course of therapy for a mean of 16 months without adverse effects. Eleven subjects failed to complete the course of therapy, with eight stopping within the first two days. One patient experienced hypotension and acute nonfatal myocardial infarction. Higher relative and absolute CD4 counts were associated with trends towards higher risk of failure.",
"     </li>",
"     <li>",
"      Another study of 22 patients used a longer nine-day protocol, which was successful in 87 percent of patients (",
"      <a class=\"graphic graphic_table graphicRef51870 \" href=\"UTD.htm?4/31/4604\">",
"       table 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/37\">",
"       37",
"      </a>",
"      ]. Reactions occurred in eight individuals (36 percent). All of these reactions consisted of mild to moderate rash or fever, which resolved after a brief course of systemic glucocorticoid treatment. There were no episodes of hypotension or anaphylaxis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We initiate all desensitization protocols under medical supervision. For patients with mild fever",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    morbilliform rash in the past, we typically administer the first three doses of this protocol in the clinic, and then allow the patient to complete the remaining steps as an outpatient. The three-day protocol is sufficiently short and it can be administered entirely in the clinic, under medical supervision. This may be preferred, for example, if the patient's ability to follow a timed schedule of doses is uncertain. In contrast, the longer nine-day protocol may be better for reliable patients in whom the main concern is introducing the medication very gradually, as the success rate of this protocol was high.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h3\">",
"     Symptoms during desensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any symptoms that develop during desensitization must be promptly evaluated in the clinic. If a patient develops mild morbilliform rash during desensitization, without fever, systemic symptoms, or mucosal involvement, then we typically reduce the dose to the last tolerated step, and administer this dose repeatedly at the usual time intervals, while simultaneously treating the rash. We treat mild rashes with antihistamines and more extensive rashes with oral glucocorticoids. When the rash begins to improve, the doses can be escalated again, although we sometimes increase the doses more gradually.",
"   </p>",
"   <p>",
"    We typically abort the desensitization protocol if fever or systemic symptoms develop.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      More rapid protocols have also been published for TMP-SMX [",
"      <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/58\">",
"       58",
"      </a>",
"      ]. These may warrant additional caution for potentially increased risks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h3\">",
"     Risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;These types of oral desensitizations are generally well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/20\">",
"     20",
"    </a>",
"    ]. However, risks of drug desensitization procedures include, but are not limited to, the entire spectrum of allergic reactions. This includes dermatologic reactions such as",
"    <span class=\"nowrap\">",
"     urticaria/angioedema",
"    </span>",
"    or other types of rash, pulmonary reactions such as asthma, and rare multi-system anaphylaxis. Other types of serious and life-threatening reactions have also been reported in association with these procedures, including myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h3\">",
"     Duration of efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desensitization may be effective only as long as the allergic individual is continuously exposed to the drug. After completing a desensitization protocol for an IgE-mediated drug reaction, the patient must continue the course of treatment without missing a single daily dose [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/59\">",
"     59",
"    </a>",
"    ]. Whether the same is true for patients desensitized to TMP-SMX, however, is speculative. Patients should be counseled that they may have a recurrent reaction if they forget to take their daily dose on one or more consecutive days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h3\">",
"     Other sulfonamides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desensitization protocols for sulfonamides other than SMX, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    (for cerebral toxoplasmosis in patients with AIDS),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    (for patients with rheumatoid arthritis or inflammatory bowel disease), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    have been published as well [",
"    <a class=\"abstract\" href=\"UTD.htm?23/2/23594/abstract/51,54,56,58\">",
"     51,54,56,58",
"    </a>",
"    ]. A protocol for sulfasalazine desensitization is provided elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/27/2490?source=see_link&amp;anchor=H14#H14\">",
"     \"Sulfasalazine in the treatment of rheumatoid arthritis\", section on 'Desensitization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Protocols for past anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desensitization protocols for patients with past anaphylaxis should only be done under the guidance of an allergy specialist with experience in such procedures. Such desensitizations are usually performed in a medically-supervised setting, with proper monitoring in place, and immediate availability of rescue medications and equipment to treat anaphylaxis. The techniques involved are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=see_link\">",
"     \"Rapid drug desensitization for immediate hypersensitivity reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Clinical characteristics and pathophysiology",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are two distinct groups of sulfonamides: antimicrobial sulfonamides and non-antimicrobial sulfonamides (",
"      <a class=\"graphic graphic_table graphicRef82011 \" href=\"UTD.htm?2/49/2845\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef57629 \" href=\"UTD.htm?31/8/31884\">",
"       table 2",
"      </a>",
"      ). Antimicrobial sulfonamides contain an arylamine group that undergoes metabolic changes believed critical to the development of hypersensitivity reactions. Medications in the non-antimicrobial group do not contain arylamine groups and are associated only rarely with hypersensitivity reactions.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       Dapsone",
"      </a>",
"      is not a sulfonamide but can cause hypersensitivity reactions that are very similar to those caused by sulfonamides (",
"      <a class=\"graphic graphic_figure graphicRef69968 \" href=\"UTD.htm?31/50/32557\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypersensitivity reactions to sulfonamide antimicrobials most commonly present as fever and morbilliform rash, sometimes accompanied by organ involvement, beginning one to two weeks after the start of therapy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Types of hypersensitivity reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sulfonamides less commonly cause other types of immunologic drug reactions, including serum sickness-like reactions and IgE-mediated allergic reactions. Sulfonamide antimicrobials are highly associated with the rare exfoliative reactions Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Types of hypersensitivity reactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     Issues of cross-reactivity",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is minimal evidence of cross-reactivity between the antimicrobial sulfonamides and the non-antimicrobial sulfonamides. However, the non-antimicrobial sulfonamides are rarely implicated in hypersensitivity reactions as well, so it is impossible to say with certainty that cross-reactivity does not occur. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Between sulfonamide antimicrobials and non-antimicrobials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is minimal evidence for cross-reactivity between antimicrobial sulfonamides and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      , and patients who react to both appear to be rare. However, celecoxib may be independently associated with a higher incidence of SJS. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Celecoxib'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is only anecdotal evidence of cross-reactivity among different non-antimicrobial sulfonamides. One important exception to this statement is the potential cross-reactivity between different sulfonamide-containing diuretics, which is suggested by case reports. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Among non-antimicrobial sulfonamides'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Evaluation and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation and diagnosis of a patient with a past sulfonamide reaction is based solely upon a detailed clinical history, because there are no useful in vitro or in vivo tests for the diagnosis of sulfonamide allergy. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'History'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h2\">",
"     Management of patients with past reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with a past reaction to a sulfonamide, the use of an alternative medication is the most suitable option in most cases, although the potential consequences of treatment failure with a \"second-best\" therapy must also be considered. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Future use of sulfonamides'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An allergy specialist should be consulted (if possible) when any form of readministration of the culprit agent or a similar medication is being considered, unless the clinician is experienced in these procedures (eg, HIV specialists). (See",
"      <a class=\"local\" href=\"#H33\">",
"       'General strategies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h3\">",
"     Fever and non-exfoliative rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a history of sulfonamide hypersensitivity (characterized by fever and non-exfoliative morbilliform rash) should avoid the causative agent and other agents in the same group (eg, within the antimicrobial arylamine group) whenever acceptable alternatives are available. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Patients with previous morbilliform rash (+/- fever)'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the culprit agent or another agent within the same group is clinically required, we suggest performing a desensitization protocol (rather than simple readministration or test dosing) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Each case requires careful consideration of risks versus benefits, particularly if the original reaction involved extracutaneous organ inflammation. (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Needing a sulfonamide from the same group'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Desensitization has been best studied in HIV-positive patients who require readministration of",
"      <span class=\"nowrap\">",
"       TMP/SMX,",
"      </span>",
"      although we have successfully desensitized patients without HIV infection to",
"      <span class=\"nowrap\">",
"       TMP/SMX",
"      </span>",
"      using the same protocols (",
"      <a class=\"graphic graphic_table graphicRef70864 \" href=\"UTD.htm?14/58/15276\">",
"       table 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef51870 \" href=\"UTD.htm?4/31/4604\">",
"       table 6",
"      </a>",
"      ). Desensitization protocols have been published for a small number of non-antimicrobial sulfonamides, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/13/28886?source=see_link\">",
"       torsemide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      , as well as for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H40\">",
"       'Desensitization'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H46\">",
"       'Other sulfonamides'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Between sulfonamide antimicrobials and dapsone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the patient requires a sulfonamide medication from a different group:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients WITHOUT other drug allergies, we suggest simply administering the desired agent normally (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients WITH other drug allergies who may be at higher risk for drug reactions in general, we suggest giving one or more test doses initially (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The necessity of this has not been systematically studied. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Needing a sulfonamide from a different group'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h3\">",
"     SJS/TEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a history consistent with SJS, TEN, or any exfoliative dermatitis due to a sulfonamide medication should STRICTLY AVOID the culprit drug and other agents in the same sulfonamide group. Reexposure to the same agent may be fatal. Use of a sulfonamide from the other group should only be considered in rare circumstances. (See",
"    <a class=\"local\" href=\"#H37\">",
"     'Patients with previous SJS or TEN'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/1\">",
"      Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 1986; 256:3358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/2\">",
"      Slatore CG, Tilles SA. Sulfonamide hypersensitivity. Immunol Allergy Clin North Am 2004; 24:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/3\">",
"      Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. Pharmacotherapy 2004; 24:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/4\">",
"      Jick H. Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients. Rev Infect Dis 1982; 4:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/5\">",
"      Phillips E, Mallal S. Drug hypersensitivity in HIV. Curr Opin Allergy Clin Immunol 2007; 7:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/6\">",
"      Lin D, Tucker MJ, Rieder MJ. Increased adverse drug reactions to antimicrobials and anticonvulsants in patients with HIV infection. Ann Pharmacother 2006; 40:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/7\">",
"      Cribb AE, Lee BL, Trepanier LA, Spielberg SP. Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis. Adverse Drug React Toxicol Rev 1996; 15:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/8\">",
"      Hemstreet BA, Page RL 2nd. Sulfonamide allergies and outcomes related to use of potentially cross-reactive drugs in hospitalized patients. Pharmacotherapy 2006; 26:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/9\">",
"      Dom&iacute;nguez-Ortega J, Mart&iacute;nez-Alonso JC, Dom&iacute;nguez-Ortega C, et al. Anaphylaxis to oral furosemide. Allergol Immunopathol (Madr) 2003; 31:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/10\">",
"      Mu&ntilde;oz-Bellido FJ, Terr&oacute;n M, Le&oacute;n A. Safety of rofecoxib in nonsteroidal anti-inflammatory drugs intolerance. Allergy 2003; 58:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/11\">",
"      Harle DG, Baldo BA, Wells JV. Drugs as allergens: detection and combining site specificities of IgE antibodies to sulfamethoxazole. Mol Immunol 1988; 25:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/12\">",
"      Chichmanian RM, Papasseudi G, Hieronimus S, et al. [Hypersensitivity to hypoglycemic sulfonylurea compounds. Are there cross-reactions?]. Therapie 1991; 46:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/13\">",
"      Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/14\">",
"      de Frutos C, de Barrio M, Tornero P, et al. Erythema multiforme from sulfaguanidine. Contact Dermatitis 2002; 46:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/15\">",
"      Forman R, Koren G, Shear NH. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience. Drug Saf 2002; 25:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/16\">",
"      Heckbert SR, Stryker WS, Coltin KL, et al. Serum sickness in children after antibiotic exposure: estimates of occurrence and morbidity in a health maintenance organization population. Am J Epidemiol 1990; 132:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/17\">",
"      Montanaro A. Sulfonamide allergy. Immunol Allergy Clin North Am 1998; 18:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/18\">",
"      Schnyder B, Mauri-Hellweg D, Zanni M, et al. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. J Clin Invest 1997; 100:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/19\">",
"      Naisbitt DJ, Farrell J, Gordon SF, et al. Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. Mol Pharmacol 2002; 62:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/20\">",
"      Solensky R. Drug desensitization. Immunol Allergy Clin North Am 2004; 24:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/21\">",
"      Asero R. Detection of patients with multiple drug allergy syndrome by elective tolerance tests. Ann Allergy Asthma Immunol 1998; 80:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/22\">",
"      Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 2003; 349:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/23\">",
"      Lee AG, Anderson R, Kardon RH, Wall M. Presumed \"sulfa allergy\" in patients with intracranial hypertension treated with acetazolamide or furosemide: cross-reactivity, myth or reality? Am J Ophthalmol 2004; 138:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/24\">",
"      Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: fact or fiction? Ann Pharmacother 2005; 39:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/25\">",
"      Shapiro LE, Knowles SR, Weber E, et al. Safety of celecoxib in individuals allergic to sulfonamide: a pilot study. Drug Saf 2003; 26:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/26\">",
"      Patterson R, Bello AE, Lefkowith J. Immunologic tolerability profile of celecoxib. Clin Ther 1999; 21:2065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/27\">",
"      La Grenade L, Lee L, Weaver J, et al. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug Saf 2005; 28:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/28\">",
"      Agrawal S, Agarwalla A. Dapsone hypersensitivity syndrome: a clinico-epidemiological review. J Dermatol 2005; 32:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/29\">",
"      Sener O, Doganci L, Safali M, et al. Severe dapsone hypersensitivity syndrome. J Investig Allergol Clin Immunol 2006; 16:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/30\">",
"      Kosseifi SG, Guha B, Nassour DN, et al. The Dapsone hypersensitivity syndrome revisited: a potentially fatal multisystem disorder with prominent hepatopulmonary manifestations. J Occup Med Toxicol 2006; 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/31\">",
"      Lorenz M, Wozel G, Schmitt J. Hypersensitivity reactions to dapsone: a systematic review. Acta Derm Venereol 2012; 92:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/32\">",
"      Sullivan TJ. Cross-reactions among furosemide, hydrochlorothiazide, and sulfonamides. JAMA 1991; 265:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/33\">",
"      Gruchalla RS, Sullivan TJ. Detection of human IgE to sulfamethoxazole by skin testing with sulfamethoxazoyl-poly-L-tyrosine. J Allergy Clin Immunol 1991; 88:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/34\">",
"      Carrington DM, Earl HS, Sullivan TJ. Studies of human IgE to a sulfonamide determinant. J Allergy Clin Immunol 1987; 79:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/35\">",
"      Neuman MG, Malkiewicz IM, Shear NH. A novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes. Clin Biochem 2000; 33:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/36\">",
"      Neuman MG, Malkiewicz IM, Phillips EJ, et al. Monitoring adverse drug reactions to sulfonamide antibiotics in human immunodeficiency virus-infected individuals. Ther Drug Monit 2002; 24:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/37\">",
"      Rich JD, Sullivan T, Greineder D, Kazanjian PH. Trimethoprim/sulfamethoxazole incremental dose regimen in human immunodeficiency virus-infected persons. Ann Allergy Asthma Immunol 1997; 79:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/38\">",
"      Rieder MJ, Uetrecht J, Shear NH, et al. Diagnosis of sulfonamide hypersensitivity reactions by in-vitro \"rechallenge\" with hydroxylamine metabolites. Ann Intern Med 1989; 110:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/39\">",
"      Carr A, Penny R, Cooper DA. Efficacy and safety of rechallenge with low-dose trimethoprim-sulphamethoxazole in previously hypersensitive HIV-infected patients. AIDS 1993; 7:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/40\">",
"      Bonfanti P, Pusterla L, Parazzini F, et al. The effectiveness of desensitization versus rechallenge treatment in HIV-positive patients with previous hypersensitivity to TMP-SMX: a randomized multicentric study. C.I.S.A.I. Group. Biomed Pharmacother 2000; 54:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/41\">",
"      Hattori N, Hino H. Generalized erythematous skin eruptions due to trimethoprim itself and co-trimoxazole. J Dermatol 1998; 25:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/42\">",
"      Ozkaya-Bayazit E, G&uuml;ng&ouml;r H. Trimethoprim-induced fixed drug eruption: positive topical provocation on previously involved and uninvolved skin. Contact Dermatitis 1998; 39:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/43\">",
"      Ozkaya-Bayazit E, Baykal C. Trimethoprim-induced linear fixed drug eruption. Br J Dermatol 1997; 137:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/44\">",
"      Moreno Escobosa MC, Cruz Granados S, Moya Quesada MC, Amat L&oacute;pez J. Enanthema and fixed drug eruption caused by trimethoprim. J Investig Allergol Clin Immunol 2009; 19:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/45\">",
"      Gruchalla RS. Diagnosis of allergic reactions to sulfonamides. Allergy 1999; 54 Suppl 58:28.",
"     </a>",
"    </li>",
"    <li>",
"     Celik G, Pichler WJ, Adkinson NF. Drug allergy. In: Middleton's allergy: Principles and practice, 7th ed, Adkinson NF, Bochner BS, Busse WW, et al (Eds), Mosby, St. Louis 2009. p.1205.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/47\">",
"      Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987; 123:1160.",
"     </a>",
"    </li>",
"    <li>",
"     Ditto AM. Drug allergy. In: Patterson's allergic diseases, 6th ed, Grammer LC, Greenberger PA. (Eds).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/49\">",
"      Earl G, Davenport J, Narula J. Furosemide challenge in patients with heart failure and adverse reactions to sulfa-containing diuretics. Ann Intern Med 2003; 138:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/50\">",
"      Wall GC, Bigner D, Craig S. Ethacrynic acid and the sulfa-sensitive patient. Arch Intern Med 2003; 163:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/51\">",
"      Juang P, Page RL 2nd, Zolty R. A successful rapid desensitization protocol in a loop diuretic allergic patient. J Card Fail 2005; 11:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/52\">",
"      Meyers S, Sachar DB, Present DH, Janowitz HD. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. Gastroenterology 1987; 93:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/53\">",
"      Taffet SL, Das KM. Desensitization of patients with inflammatory bowel disease to sulfasalazine. Am J Med 1982; 73:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/54\">",
"      Purdy BH, Philips DM, Summers RW. Desensitization for sulfasalazine skin rash. Ann Intern Med 1984; 100:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/55\">",
"      K&uuml;mmerle-Deschner J, Dannecker G. Sulphasalazine desensitization in a paediatric patient with juvenile chronic arthritis. Acta Paediatr 1995; 84:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/56\">",
"      Bax DE, Amos RS. Sulphasalazine in rheumatoid arthritis: desensitising the patient with a skin rash. Ann Rheum Dis 1986; 45:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/57\">",
"      Caumes E, Guermonprez G, Lecomte C, et al. Efficacy and safety of desensitization with sulfamethoxazole and trimethoprim in 48 previously hypersensitive patients infected with human immunodeficiency virus. Arch Dermatol 1997; 133:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/58\">",
"      Moreno JN, Poblete RB, Maggio C, et al. Rapid oral desensitization for sulfonamides in patients with the acquired immunodeficiency syndrome. Ann Allergy Asthma Immunol 1995; 74:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/2/23594/abstract/59\">",
"      deShazo RD, Kemp SF. Allergic reactions to drugs and biologic agents. JAMA 1997; 278:1895.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2080 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-00FF42CD0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_2_23594=[""].join("\n");
var outline_f23_2_23594=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H48\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Types of sulfonamides",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Antimicrobial sulfonamides",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Non-antimicrobial sulfonamides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Sulfones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Medications unrelated to sulfonamides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Impact of HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TYPES OF HYPERSENSITIVITY REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Isolated cutaneous reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Morbilliform rash with fever and systemic symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Immediate-type allergy and anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other uncommon reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Serum sickness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Hemolytic anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Sulfonamide metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CROSS-REACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Confounding in studies of cross-reactivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Between sulfonamide antimicrobials and non-antimicrobials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Celecoxib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Between sulfonamide antimicrobials and dapsone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Among non-antimicrobial sulfonamides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Referral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Trimethoprim allergy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      FUTURE USE OF SULFONAMIDES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      General strategies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27348531\">",
"      Precautions with any form of reexposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Patients with previous morbilliform rash (+/- fever)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Needing a sulfonamide from a different group",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Needing a sulfonamide from the same group",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Patients with previous SJS or TEN",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Needing a sulfonamide from a different group",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Patients with past anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      DESENSITIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Protocols for past rash/fever",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Trimethoprim-sulfamethoxazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      - Symptoms during desensitization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      - Risks",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      - Duration of efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      - Other sulfonamides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Protocols for past anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Clinical characteristics and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      Issues of cross-reactivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      Management of patients with past reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      - Fever and non-exfoliative rash",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      - SJS/TEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2080\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2080|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/11/39100\" title=\"figure 1\">",
"      Sulfonamide antimicrobial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/60/9154\" title=\"figure 2\">",
"      Sulfonamide structures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/50/32557\" title=\"figure 3\">",
"      Dapsone structure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/17/31006\" title=\"figure 4\">",
"      Sulfonamide metabolic pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2080|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/49/2845\" title=\"table 1\">",
"      Antimicrobial sulf",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/8/31884\" title=\"table 2\">",
"      Non antimicrobial sulf",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/11/13500\" title=\"table 3\">",
"      Types allergic reactions SS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/59/18363\" title=\"table 4\">",
"      Sulfonamide agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/58/15276\" title=\"table 5\">",
"      TMP-SMX desens 3 day po",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/31/4604\" title=\"table 6\">",
"      TMP-SMX desens 9 day po",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40681?source=related_link\">",
"      Allergic and asthmatic reactions to food additives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24554?source=related_link\">",
"      An approach to the patient with drug allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=related_link\">",
"      Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38456?source=related_link\">",
"      Drug allergy: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2456?source=related_link\">",
"      Drug fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13754?source=related_link\">",
"      Drugs and the liver: Metabolism and mechanisms of injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=related_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=related_link\">",
"      Management of severe ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=related_link\">",
"      Rapid drug desensitization for immediate hypersensitivity reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8842?source=related_link\">",
"      Serum sickness and serum sickness-like reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/27/2490?source=related_link\">",
"      Sulfasalazine in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_2_23595="Examination of disabled women";
var content_f23_2_23595=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51647&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51647&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Facilitating the gynecologic examination of disabled women",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Make modifications in office layout and equipment and train staff to meet the physical and informational needs of disabled patients. In particular, the office should be accessible; communication should be possible despite cognitive or sensory impairment; and staff should be trained in safe techniques for transfer of the patient to the examining table.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ask if the woman feels her disability affects her reproductive functions. Address all gynecologic issues, as appropriate: sexual activity, contraception, menstrual cycles, cancer screening, preconceptional issues, menopause, and osteoporosis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Understand the medical issues of patients with disabilities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allow extra time for the appointment and have extra staff available, if needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inquire about a history of physical or sexual abuse as these women are at increased risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A frog-legged or lateral position may be easier to achieve than the lithotomy position for examination. If examination is still not possible, use of ultrasonography, sedation, or anesthesia are options.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from American College of Obstetricians and Gynecologists. Women with Disabilities. In: Guidelines for Women's Health Care. 2nd edition, Washington, DC, 2002.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_2_23595=[""].join("\n");
var outline_f23_2_23595=null;
var title_f23_2_23596="Fetal radiation exposure";
var content_f23_2_23596=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimated average fetal radiation exposure from selected imaging studies performed on the mother during pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Procedure",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fetal dose (mrad) for an average study",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest x-ray (PA and lateral)",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal plain film",
"       </td>",
"       <td>",
"        200 to 300",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intravenous pyelogram",
"       </td>",
"       <td>",
"        400 to 900",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Barium enema",
"       </td>",
"       <td>",
"        700 to 1600",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cervical spine x-ray",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dorsal spine x-ray",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lumbar spine x-ray",
"       </td>",
"       <td>",
"        400 to 600",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lumbosacral area",
"       </td>",
"       <td>",
"        200 to 600",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Upper GI series",
"       </td>",
"       <td>",
"        50 to 400",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hip and femur x-ray",
"       </td>",
"       <td>",
"        100 to 400",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dental x-rays",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mammography",
"       </td>",
"       <td>",
"        Negligible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebral angiography",
"       </td>",
"       <td>",
"        &lt;10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CT of the chest",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CT of the abdomen",
"       </td>",
"       <td>",
"        250",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perfusion lung scan with 99Tc",
"       </td>",
"       <td>",
"        6 to 12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ventilation lung scan",
"       </td>",
"       <td>",
"        1 to 19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary angiography via femoral route",
"       </td>",
"       <td>",
"        221 to 374",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary angiography via brachial route",
"       </td>",
"       <td>",
"        &lt;50",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Bentur Y. Ionizing and nonionizing radiation in pregnancy. In: Maternal-fetal toxicology, 2nd ed, Koren G (Ed), Marcel Dekker, New York, 1994, p. 515, and Guidelines on diagnosis and management of acute pulmonary embolism. Task Force on Pulmonary Embolism, European Society of Cardiology. Eur Heart J 2000; 21:1301.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_2_23596=[""].join("\n");
var outline_f23_2_23596=null;
var title_f23_2_23597="Contents: Behavioral and cognitive neurology";
var content_f23_2_23597=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?0/63/1022\">",
"       Neurology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Behavioral and cognitive neurology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Behavioral and cognitive neurology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/48/23303\">",
"           The mental status examination in adults",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-FDF83A3A2F-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f23_2_23597=[""].join("\n");
var outline_f23_2_23597=null;
var title_f23_2_23598="Mortality with syncope by cause";
var content_f23_2_23598=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Overall survival of patients with syncope",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 324px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Survival was worst for patients with a cardiovascular cause of syncope. P &lt;0.001 for the comparison between participants with and those without syncope. The category \"Vasovagal and other causes\" includes vasovagal, orthostatic, medication-induced, and other, infrequent cause of syncope.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Sorteriades ES, Evans JC, Larson MG, et al. Incidence and prognosis of syncope. N Engl J Med 2002; 347:878.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_2_23598=[""].join("\n");
var outline_f23_2_23598=null;
var title_f23_2_23599="IgA nephropathy IF";
var content_f23_2_23599=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F69895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F69895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Immunofluorescence microscopy showing mesangial IgA deposits",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 394px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immunofluorescence microscopy demonstrating large, globular mesangial IgA deposits that are diagnostic of IgA nephropathy or Henoch-Sch&ouml;nlein purpura (IgA vasculitis). Note that the capillary walls are not outlined since the deposits are primarily limited to the mesangium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_2_23599=[""].join("\n");
var outline_f23_2_23599=null;
